U.S. patent application number 11/828272 was filed with the patent office on 2008-01-10 for polynucleotide fragments of an infectious human endogenous retrovirus.
This patent application is currently assigned to AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH AG. Invention is credited to Andreas Grassauer, Thomas Muster, Hubert Pehamberger, Klaus Wolff.
Application Number | 20080008717 11/828272 |
Document ID | / |
Family ID | 3688328 |
Filed Date | 2008-01-10 |
United States Patent
Application |
20080008717 |
Kind Code |
A1 |
Wolff; Klaus ; et
al. |
January 10, 2008 |
Polynucleotide Fragments of an Infectious Human Endogenous
Retrovirus
Abstract
Nucleotide sequences and fragments which code for a human
endogenous retrovirus which is infectious. "Fragments" according to
the present invention relate also to specific fragments of the
sequences inserted into the vector pCR4-Topo and deposited as
MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above.
Additionally, methods of using such sequences, polypeptides encoded
by such sequences, antibodies directs against such sequences, and
methods and compositions relating to the same are all
contemplated.
Inventors: |
Wolff; Klaus; (Vienna,
AT) ; Pehamberger; Hubert; (Vienna, AT) ;
Grassauer; Andreas; (Vienna, AT) ; Muster;
Thomas; (Vienna, AT) |
Correspondence
Address: |
FULBRIGHT & JAWORSKI L.L.P.
600 CONGRESS AVE.
SUITE 2400
AUSTIN
TX
78701
US
|
Assignee: |
AVIR GREEN HILLS BIOTECHNOLOGY
RESEARCH AG
Gersthofer Strasse 29-31
Vienna
AT
A-1180
|
Family ID: |
3688328 |
Appl. No.: |
11/828272 |
Filed: |
July 25, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10490920 |
Mar 26, 2004 |
|
|
|
PCT/EP02/10899 |
Sep 27, 2002 |
|
|
|
11828272 |
Jul 25, 2007 |
|
|
|
Current U.S.
Class: |
424/159.1 ;
424/207.1; 424/93.6; 530/389.4 |
Current CPC
Class: |
C07K 14/005 20130101;
C12N 2740/10022 20130101; A61P 31/14 20180101; G01N 2333/15
20130101; G01N 33/5743 20130101; A61K 38/00 20130101; G01N 33/56983
20130101; C12N 2740/10021 20130101; A61K 2039/5254 20130101; C12N
7/00 20130101; A61K 39/00 20130101 |
Class at
Publication: |
424/159.1 ;
424/207.1; 424/093.6; 530/389.4 |
International
Class: |
A61K 48/00 20060101
A61K048/00; A61K 35/76 20060101 A61K035/76; A61K 39/21 20060101
A61K039/21; C07K 16/08 20060101 C07K016/08; A61K 39/395 20060101
A61K039/395 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 27, 2001 |
AT |
1539/2001 |
Claims
1-90. (canceled)
91. An antibody or fragment thereof directed against a polypeptide
encoded by a polynucleotide molecule comprising all or a fragment
of a nucleotide sequence of an infectious human endogenous
retrovirus, which sequence is or is complementary to a sequence
which: (a) has at least 98% identity to a sequence of SEQ ID NO: 1
or a fragment thereof; (b) hybridizes under stringent conditions
with a nucleotide sequence of said SEQ ID NO: 1 or a fragment
thereof; (c) differs from the sequences of (a) and/or (b) due to
degeneration of the genetic code; and/or (d) comprises a sequence
inserted into a vector pCR4-Topo and deposited as any of
"MERV-env", "MERV-gag", "MERV-prt" and "MERV-pol" at the DSMZ on 26
Sep. 2001 or a fragment of such a sequence.
92. The antibody or antibody fragment of claim 91, further defined
as attached to the surface of a solid support.
93. The antibody or antibody fragment of claim 91, wherein the
polynucleotide molecule is further defined as comprising the
sequence of SEQ ID NO: 1 or a fragment thereof.
94. The antibody or antibody fragment of claim 91, wherein the
polynucleotide molecule is further defined as comprising a specific
fragment with a length of at least 15 bp of SEQ ID NO: 1.
95. The antibody or antibody fragment of claim 91, wherein the
polynucleotide molecule is further defined as comprising a specific
fragment of SEQ ID NO:1, wherein the fragment is defined as having
a sequence identical to SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or
SEQ ID NO:5.
96. The antibody or antibody fragment of claim 91, wherein the
polynucleotide molecule is further defined as encoding an env
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
99.5% identity to a sequence of SEQ ID NO:2; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:2; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-env" or a fragment of that sequence.
97. The antibody or antibody fragment of claim 91, wherein the
polynucleotide molecule is further defined as encoding a gag
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
99.5% identity to a sequence of SEQ ID NO:4; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:4; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-gag" or a fragment of that sequence.
98. The antibody or antibody fragment of claim 91, wherein the
polynucleotide molecule is further defined as encoding a pro
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
98% identity to a sequence of SEQ ID NO:5; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:5; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-prt" or a fragment of that sequence.
99. The antibody or antibody fragment of claim 91, wherein the
polynucleotide molecule is further defined as encoding a pol
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
99% identity to a sequence of SEQ ID NO:3; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:3; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-pol" or a fragment of that sequence.
100. A pharmaceutical composition comprising a polynucleotide
molecule comprising a base sequence complementary to the sequence
of a polynucleotide molecule comprising all or a fragment of a
nucleotide sequence of an infectious human endogenous retrovirus,
which sequence is or is complementary to a sequence which: (a) has
at least 98% identity to a sequence of SEQ ID NO:1 or a fragment
thereof; (b) hybridizes under stringent conditions with a
nucleotide sequence of said SEQ ID NO:1 or a fragment thereof; (c)
differs from the sequences of (a) and/or (b) due to degeneration of
the genetic code; and/or (d) comprises a sequence inserted into a
vector pCR4-Topo and deposited as any of "MERV-env", "MERV-gag",
"MERV-prt" and "MERV-pol" at the DSMZ on 26 Sep. 2001 or a fragment
of such a sequence; a vector comprising such a polynucleotide
molecule, an infectious or attenuated human endogenous retrovirus
encoded by such a polynucleotide molecule, an antibody or antibody
fragment directed against a polypeptide encoded by such a
polynucleotide molecule or against an infectious or attenuated
human endogenous retrovirus, or a PNA molecule comprising a base
sequence of such a molecule in a pharmaceutically acceptable
carrier.
101. The pharmaceutical composition of claim 100, further defined
as attached to the surface of a solid support.
102. The pharmaceutical composition of claim 100, wherein the
polynucleotide molecule is further defined as comprising the
sequence of SEQ ID NO:1 or a fragment thereof.
103. The pharmaceutical composition of claim 100, wherein the
polynucleotide molecule is further defined as comprising a specific
fragment with a length of at least 15 bp of SEQ ID NO:1.
104. The pharmaceutical composition of claim 100, wherein the
polynucleotide molecule is further defined as comprising a specific
fragment of SEQ ID NO:1, wherein the fragment is defined as having
a sequence identical to SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or
SEQ ID NO:5.
105. The pharmaceutical composition of claim 100, wherein the
polynucleotide molecule is further defined as encoding an env
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
99.5% identity to a sequence of SEQ ID NO:2; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:2; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-env" or a fragment of that sequence.
106. The pharmaceutical composition of claim 100, wherein the
polynucleotide molecule is further defined as encoding a gag
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
99.5% identity to a sequence of SEQ ID NO:4; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:4; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-gag" or a fragment of that sequence.
107. The pharmaceutical composition of claim 100, wherein the
polynucleotide molecule is further defined as encoding a pro
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
98% identity to a sequence of SEQ ID NO:5; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:5; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-prt" or a fragment of that sequence.
108. The pharmaceutical composition of claim 100, wherein the
polynucleotide molecule is further defined as encoding a pol
protein of an infectious human endogenous retrovirus, said
polynucleotide molecule comprising a sequence: (a) with at least
99% identity to a sequence of SEQ ID NO:3; (b) which hybridizes
under stringent conditions with a nucleotide sequence of said SEQ
ID NO:3; (c) which differs from the sequences of (a) and/or (b) due
to degeneration of the genetic code; and/or (d) comprises the
sequence inserted into a vector pCR4-Topo and deposited as
"MERV-pol" or a fragment of that sequence.
109. The pharmaceutical composition of claim 100, further
comprising at least one antiviral substance.
110. The pharmaceutical composition of claim 100, further defined
as a sun cream.
111. The pharmaceutical composition of claim 100, further defined
as a vaccine.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of co-pending U.S.
application Ser. No. 10/490,920 filed 26 Mar. 2004, which is a
national phase application under 35 U.S.C. .sctn. 371 of
International Application No. PCT/EP02/10899 filed 27 Sep. 2002,
which claims priority to Austrian Application No. A 1539/2001 filed
27 Sep. 2001, the contents of which are incorporated herein by
reference in their entirety.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates to human endogenous
retroviruses, fragments thereof, a biologically functional vector
comprising sequences of said retrovirus.
[0004] 2. Description of Related Art
[0005] Endogenous retroviruses (ERVs) are integral parts in the
genomes of many, if not of all, species. ERVs most probably
resulted from infection of germ line cells with exogenous
retroviruses and subsequent fixation of their genetic information
in the host genome.
[0006] Many types of human endogenous retroviruses (HERVs) have
been characterized previously, and they have been classified into
different groups, or families, partly on the basis of their
sequence identity and partly according to the similarity of their
primer binding sites (PBSs) to host tRNAs. Thus, members of the
HERV.H family contain a PBS with a sequence similar to a region of
tRNA.sup.His, whereas the HERV.E family is primed by tRNA.sup.Glu.
Despite the large amount of data available, the classification of
the many different HERV families within an overall phylogenetic
framework has been hampered for several reasons: (i) some highly
divergent retroviruses are primed by the same type of tRNA; (ii)
many HERV families have not been fully characterized, and the
sequence information that has been reported is often derived from
different genomic regions, making interfamily comparisons
problematic; and (iii) the relative lack of sequence information on
other host taxa has made it difficult to distinguish between
genuinely monophyletic HERV families and polyphyletic families that
appear monophyletic only because similar viruses in other hosts
have not yet been described. A pathogenic potential of nondefective
endogenous retroviruses has so far only been demonstrated in mice,
in which they may induce tumors and immunological disorders. In
human DNA, endogenous retrovirus sequences (HERVs) are well known
genetic elements. They all seem to be defective due to multiple
termination codons, deletions, or the lack of a 5' long terminal
repeat (LTR). Replication competent human endogenous retrovirus
genomes have not yet been isolated.
[0007] Extensive studies on animal melanomas (especially that of
the hamster), which serve as model for human malignant melanoma
have shown the occurrence of virus particles in the tumors. A high
molecular weight (70S) RNA species as well as an RNA-directed DNA
polymerase, two diagnostic features for oncoma (oncogenic RNA)
viruses have been associated with these particles. Cell-free
transmission experiments end to the conclusion that hamster
melanomas are caused by an RNA virus.
[0008] Based on these findings the working hypothesis was proposed
that human melanoma may also have a viral etiology. In experiments
the occurrence of virus-like particles as well as reverse
transcriptase activity in metastases of human melanoma was reported
in the early 70s. (Birkmayer et al., Europ. J. Cancer 10 (1974)
419-422).
[0009] These virus-like particles are spherical or slightly ovoid
and have a diameter of 90-120 nm. They have an electron-dense
nucleoid measuring 50-70 nm across and are bounded by a
triple-layered, 100 .ANG. thick membrane. Sometimes fine
projections extend radially from the nucleoid towards the membrane,
and in this case the particles resemble those found in hamster
melanoma. Their number is rather small in comparison to that found
in hamster melanoma. So far, they have been seen only in the
cytoplasm and no infectivity has been observed for these particles
(Birkmayer et al., Die Naturwissenschaften 59 (8) (1972),
369-370).
[0010] Also Balda et al. (Proc. Nat. Acad. Sci, USA 72 (9) (1975,
3697-3700) described a high molecular weight RNA encapsulated with
an RNA extracted DNA polymerase in particles possessing the
identity characteristic of the RNA tumor viruses which was detected
in human malignant melanomas. However, also here no infectious
particles were observed.
[0011] Only many years later the expression of a family of human
endogenous retrovirus sequences (HERV-K) in GH cells, a
teratocarcinoma cell line producing the human
teratocarcinoma-derived retrovirus (HTDV) particles was described
(Lower et al., Proc. Natl. Acad. Sci. USA 90 (1993): 4480-4484).
Detailed electron microscopic surveys have revealed the existence
of retrovirus-like particles in human placentas and teratocarcinoma
cell lines. However, these found HERV-K/HTDV particles were also
not infectious: They possess a distinct morphology: (i) they lack
the electron lucent space normally seen between viral envelope and
core, (ii) they seem to be predominantly arrested in budding
stages, and (iii) collapsed cores, a consequence of a final
proteolytic step in virus maturation, have never been observed. As
long as the gag precursor remains uncleaved, resulting particles
are not likely to be infectious.
[0012] A further HERV-K provirus was shown to be present in gorilla
and chimpanzee genomes but not in the human genome (Barbulescu et
al., Current Biology 11 (10) (2001), 779-783).
[0013] Therefore, human endogenous retroviruses have shown to be
expressed, however, these virus particles found up to date were all
non-infectious virus particles. Some endogenous retrovirus-like
particles were found to be expressed in melanoma cells. However,
the only infectious endogenous retroviruses found were some animal
endogenous retroviruses, e.g. MelARV, a retrovirus capable of
infecting cultured murine melanocytes which have also been shown to
induce in some instances malignant transformation.
[0014] In the article by Reus et al. (Journal of Virology, October
2001, 8917-8926) it is stated that the average age of HERV-K
proviruses is ca. 28 million years. It is described that at that
time the HERV-Ks probably used to be infectious.
[0015] The WO 01/62937 A1 relates to retrovirus sequences and
psoriasis.
[0016] In the WO 00/53789 A1 various retroviral expression vectors
are listed.
[0017] The WO 00/20460 A1 relates to the detection of a HERV-K10
gag-sequence which is brought into relationship with the cancer
seminoma, whereby the HERV-K10 gag-sequence is used as tumor marker
as well as for therapeutic methods.
[0018] In the WO 00/06598 A1 a HERV-AVL3-B sequence fragment is
brought in connection with methods for the treatment for malign
melanomas.
[0019] The WO 99/67395 A1 relates to a 600 bp sequence of an
env-gene of a virus family HERV-7q and relates to the use for or in
connection with multiple sclerosis, and autoimmune diseases,
respectively.
[0020] In the WO 98/24454 A1 the use of a retroviral ribozyme
sequence HERV-PTN for the inhibition of tumor growth is
described.
[0021] The JP 9252780 A relates to a method, in which a retrovirus
polypeptide of the type HERV-E as a surrogate marker for cancer and
other illnesses is detected.
[0022] The WO 01/70941 A2 relates to a retroviral sequence with
high homology to the family HERV-H, whereby this sequence is
brought into connection with multiple sclerosis.
[0023] The DE 198 11 692 A1 relates to a preparation for the
protection against sun rays which is effective against herpes
simplex viruses, whereby the preparation comprises organic and
anorganic light filters.
SUMMARY OF THE INVENTION
[0024] The object of the present invention is therefore to provide
at least a fragment of a nucleotide sequence which codes for a
further human endogenous retrovirus which is infectious.
[0025] The object of the present invention is solved by a
polynucleotide molecule being a fragment of a nucleotide sequence
of an infectious human endogenous retrovirus which polynucleotide
molecule comprises a sequence selected from the group consisting of
[0026] (a) a sequence with at least 98%, preferably 99%, still
preferred 99.5%, identity to a sequence according to SEQ ID No 1,
[0027] (b) a sequence which hybridizes under stringent conditions
with a nucleotide sequence according to said SEQ ID No 1, [0028]
(c) a sequence which differs from said sequences (a) or (b) due to
degeneration of the genetic code and [0029] (d) a sequence
comprising sequences inserted into vectors pCR4-Topo and deposited
as "MERV-env", "MERV-gag", "MERV-prt" and "MERV-pol" at the DSMZ on
26 Sep. 2001 or fragments thereof.
[0030] It has been surprisingly found that a polynucleotide
molecule as mentioned above codes for (parts of) an infectious
human endogenous retrovirus. With the present invention it can be
shown for the first time that not only infectious animal endogenous
retroviruses exist but also infectious human endogenous
retroviruses. This is particularly surprising due to the fact that
human endogenous retroviruses have been known and described for
more than 30 years, however, even though many groups have been
carrying out research in this field over decades, infectious human
endogenous retroviruses could not be isolated or detected so
far.
[0031] The polynucleotide molecule according to the present
invention is preferably an isolated and a purified DNA or RNA
molecule.
[0032] "Infectious" in the scope of the present application relates
especially to retrovirus particles which are able to bind to the
receptor of a cell over the env protein and enter into the cell and
carry out a reverse transcription in order to produce a cDNA which
can integrate into the host cell DNA. The differences between the
life cycles of different retro elements and between infectious and
non-infectious retroviruses is described in the article by Lower et
al. (Proc. Natl. Acad. Sci 93 (1996), 5177-5184), which is
incorporated herein by reference.
[0033] Preferably, "infectious" human endogenous retroviruses
according to the present invention are able to infect bovine MDBK
cells and to integrate into these cells' genome.
[0034] The sequence according to SEQ ID NO 1 comprises a region
which must be present in the polynucleotide molecule in order to
code for an infectious human endogenous retrovirus (HERV). However,
at both ends the polynucleotide molecule according to the present
invention can comprise further herein not specifically described
sequence regions, in particular LTR regions common to such viruses.
With the present polynucleotide molecule any here not defined
sequence regions can be identified by e.g. amplifying these
sequences with the help of optimally designed gene specific primers
which will for example bind to the above defined sequence regions.
The amplification products can then be sequenced. Such methods are
well known to the person skilled in the art.
[0035] "Stringent conditions" relate to hybridization reactions
under defined hybridization conditions which is a function of
factors as concentration of salt or formamide in the hybridization
buffer, the temperature of the hybridization and the
post-hybridization wash conditions. Such conditions for Northern
Blot analysis are for example hybridization at 68.degree. C. with a
MERV-specific polynucleotide molecule labeled with dioxigenin or
radioactive in a standard SSC hybridization buffer containing 0.1%
SDS followed by stringent washing in wash buffer at the same
temperature. Stringent washing can be performed for example by two
times washing with 2.times.SSC buffer followed by two wash steps
with 0.5.times.SSC buffer. In the present case stringent
hybridization conditions will preferably involve a temperature of
15.degree. C. to 25.degree. C. below the melting temperature (Tm),
whereby the Tm of a hybridization product of a nucleic acid probe
can be calculated using a formula based on the g+c contained in the
nucleic acids and that takes chain lengths into account, such as
the formula Tm=81.5 to 16.6 (log [na.sup.+])+0.41 (% G+C)-600/N),
wherein N=chain length (Sambrook et al. (1989), which is
incorporated herein by reference). In practice an estimated Tm for
an oligonucleotide probe is often confirmed and thus a person
skilled in the art can calculate the Tm for any chosen probe whose
nucleotide sequence is known.
[0036] Sequences which differ from a given sequence due to the
degeneration of the genetic code can be defined by any person
skilled in the art. This can be carried out electronically without
undue burden.
[0037] In the scope of the present application the deposited
vectors MERV-env, MERV-gag, MERV-prt and MERV-pol refer to plasmids
deposited at the DSMZ (Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH) according to the Budapest Treaty and comprise
the accession numbers DSM1450, DSM14538, DSM14536 and DSM14537.
[0038] In the scope of the present invention, when sequences
inserted into the deposited vectors are concerned not only
identical sequences are referred to but also sequences [0039] (a)
with at least 98%, preferably 99%, still preferred 99.5%, identity
to the sequences inserted into the deposited vectors, [0040] (b)
which hybridize under stringent conditions with sequences inserted
into the deposited vectors and [0041] (c) which differ from said
sequences inserted into the deposited vectors due to degeneration
of the genetic code.
[0042] The above polynucleotide molecule according to the present
invention may further comprise a sequence which is at least 99.7%,
99.8% or 99.9% identical to SEQ ID NO 1.
[0043] Preferably, the polynucleotide molecule comprises a sequence
according to SEQ ID NO 1 and is therefore identical to SEQ ID NO 1.
This polynucleotide molecule has shown to code for a complete and
active infectious particle of a HERV. The ORFs of SEQ ID NO 1 are
preferably as follows: TABLE-US-00001 ORF Nucleotides genetic code
gag 1-2013 universal prt 1993-2809 nested reading frame pol
3032-5650 universal env 5352-7451 universal
[0044] Still preferred a polynucleotide molecule is provided which
comprises a specific fragment of said above described
polynucleotide molecule with a length of at least 15 bp, preferably
at least 20 bp, still preferred at least 30 bp. The term "specific"
defines any fragment which comprises a sequence different to any
known HERV sequence. Therefore, any fragment with a length of at
least 15 bp which comprises, for example, the in Table 1 mentioned
mutations with respect to the known non-infectious HERV K
(GeneBank, accession nr. 164614) will be comprised by the
polynucleotide molecule according to the present invention.
However, these given lengths are minimum lengths and also fragments
which are longer, e.g. 100, 1000, 1500 bp, are also comprised by
the term "fragment".
[0045] "Fragments" according to the present invention relate also
to specific fragments of the sequences inserted into the vector
pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and
MERV-pol as mentioned above. TABLE-US-00002 TABLE 1 position in
amino acid position HERV K108 change in (Accession nucleotide
change (MERV/ clone name MERV 164614) (MERV/HERV) HERV) MERV gag
416 1515 C/T Ala/Val 602 1701 C/A Arg/Lys 630 1729 A/G Pro/Pro 639
1738 T/C Ala/Ala 654 1753 G/T Pro/Pro 738 1837 G/A Pro/Pro 799 1898
G/A Glu/Lys 802 1901 C/T Leu/leu 866 1965 T/C Met/Thr 945 2044 A/G
Ser/Ser 953 2052 T/A Met/Lys 972 2071 A/G Glu/Glu 1149 2248 A/G
Gln/Arg 1348 2447 A/G Lys/Gly 1413 2512 C/T Ala/Ala 1642 2741 G/A
Gly/Arg 1653 2752 C/T Tyr/Tyr 1668 2767 C/T Ile/Ile 1701 2800 C/T
Asn/Asn 1989 3088 A/G Pro/Pro MERV prot 2068 3167 T/C Ile/Thr 2087
3186 C/A Gly/Gly 2090 3189 A/C Pro/Pro 2097 3196 G/A Glu/Lys 2100
3199 A/G Arg/Gly 2124 3223 A/C Arg/Arg 2163 3262 G/A Gly/Ser 2198
3297 G/A Gln/Gln 2238 3337 G/A Gly/Arg 2253 3352 G/C Glu/Gln 2273
3372 T/C Tyr/Tyr 2305 3404 C/T Thr/Ile 2313 3412 T/C Phe/Leu 2330
3429 G/A Pro/Pro 2461 3560 G/A Arg/Gln 2501 3600 T/A Gly/Gly 2502
3601 T/C Phe/Leu 2543 3642 T/G Thr/Thr 2554 3653 G/A Arg/His 2590
3689 G/A Arg/Gln 2654 3753 A/G Ala/Ala 2659-2661 3758-3760 --/ATC
--/Ile 2677 3776 T/C Leu/Ser 2741 3840 A/G Gly/Gly 2763 3862 G/A
Val/Ile 2808 3907 T/A Tyr/Asn 2815 3914 T/G Phe/Cys 2816 3915 T/C
Phe/Cys MERV prot 2878 3977 G/A Arg/Gln 2938 4037 G/A Arg/Gln 2974
4073 A/G His/Arg 3052 4151 C/T Ala/Ala 3091 4190 T/C Pro/Pro 3105
4204 T/C Leu/Pro 3124 4223 C/T Leu/Asp 3178 4277 G/A Ala/Ala MERV
pol 3363 4462 A/G Tyr/Cys 3664 4763 A/C Ile/Ile 3700 4799 A/G
Ile/Met 4040 5139 C/A Gln/Lys 4115 5214 A/T Met/Leu 4219 5318 G/A
Gly/Gly 4225 5324 G/A Lys/Lys 4255 5354 T/G Ser/Ser 4336 5435 C/A
Ala/Ala 4465 5564 T/A Thr/Thr 4517 5616 G/C Glu/Gln 4771 5870 G/A
Ser/Ser 4780 5879 T/C His/His MERV env 5402 6501 C/T His/His 5719
6818 T/C Ile/Thr 6456 7555 G/A Val/Ile 6458 7557 C/T Val/Ile 6464
7563 A/G Leu/Leu 6802 7901 G/C Gly/Ala 7146 8245 A/G Lys/Glu 7262
8361 A/G Thr/Thr 7340 8439 G/A Arg/Arg 7347 8446 A/G Asn/Asp 7388
8487 A/G Ser/Ser 7436 8535 C/T Val/Val
[0046] According to a preferred embodiment of the present invention
a polynucleotide molecule encoding for an env protein of an
infectious endogenous human retrovirus is provided, said
polynucleotide molecule comprising a sequence selected from the
group consisting of
[0047] (a) a sequence with at least 98%, preferably 99%, still
preferred 99.5%, identity to a sequence according to SEQ ID No
2,
[0048] (b) a sequence which hybridizes under stringent conditions
with a nucleotide sequence according to said SEQ ID No 2 and
[0049] (c) a sequence which differs from said sequence (a) or (b)
due to degeneration of the genetic code.
[0050] "Env" according to the present invention relates also to the
sequence inserted into the deposited MERV-env plasmid as mentioned
above or a fragment thereof.
[0051] It is known that retroviruses are "quasispecies" and
sequence variation in a given virus population is given. Such
quasispecies variations are, of course, included in the definition
of the present viruses and of the sequences of the nucleic acid
molecules according to the present invention as long as the
infectivity of the virus population as a whole is given.
[0052] "Env" relates to the envelope protein which is a viral
membrane protein mediating the binding of the virus particles to
the cellular receptors enabling virus entry which is the first step
in a new replication cycle. The env protein is particularly
important for the ability to spread between cells and individuals
(infectivity).
[0053] A further embodiment of the present invention relates to a
polynucleotide molecule encoding for a pol protein of a HERV,
whereby said polynucleotide molecule comprises a sequence selected
from the group consisting of
[0054] (a) a sequence with at least 99%, preferably 99.5%, still
preferred 99.8%, identity to a sequence according to SEQ ID No
3,
[0055] (b) a sequence which hybridizes under stringent conditions
with a nucleotide sequence according to said SEQ ID No 3 and
[0056] (c) a sequence which differs from said sequence (a) or (b)
due to degeneration of the genetic code. "pol" relates to the
polymerase which is an enzyme with RNA dependant reverse
transcriptase activity. Also this protein is important for a
correct viral replication cycle.
[0057] "Pol" according to the present invention relates also to the
sequence inserted into the deposited MERV-pol plasmid as mentioned
above or a fragment thereof.
[0058] A still further aspect of the present invention relates to a
polynucleotide molecule encoding for a gag protein of a HERV,
whereby said polynucleotide molecule comprises a sequence selected
from the group consisting of
[0059] (a) a sequence with at least 98%, preferably 99%, still
preferred 99.5%, identity to a sequence according to SEQ ID No
4,
[0060] (b) a sequence which hybridizes under stringent conditions
with a nucleotide sequence according to said SEQ ID No 4 and
[0061] (c) a sequence which differs from said sequence (a) or (b)
due to degeneration of the genetic code.
[0062] The gag gene products have acquired the ability to be
transported to the cell surface and abut on the cell membrane
incorporating env proteins during this process. The gag gene codes
for a long polyprotein which in a first step is cut from the long
molecule chain and is then cut into a number of parts which are
present around the RNA in form of capsomeres. Since these gag
proteins are essential for the budding they are important for the
infectious viral circle.
[0063] "Gag" according to the present invention relates also to the
sequence inserted into the deposited MERV-gag plasmid as mentioned
above or a fragment thereof.
[0064] A further embodiment relates to a polynucleotide molecule
encoding for a pro protein of a HERV, whereby said polynucleotide
molecule comprises a sequence selected from the group consisting
of
[0065] (a) a sequence with at least 98%, preferably 99%, still
preferred 99.5%, identity to a sequence according to SEQ ID No
5,
[0066] (b) a sequence which hybridizes under stringent conditions
with a nucleotide sequence according to said SEQ ID No 5 and
[0067] (c) a sequence which differs from said sequence (a) or (b)
due to degeneration of the genetic code.
[0068] The pro gene comprises 3 regions of particular interest:
[0069] 1. dUTPase, dUTPase hydrolyses dUTP to dUMP and
pyrophosphate.
[0070] 2. prt retroviral Aspartyl-Proteinase
[0071] 3. G_patch, .alpha.-glycine rich nucleic binding domain; A
predicted glycine rich nucleic binding domain found in the splicing
factor 45, SON DNA binding protein and D-type Retrovirus-
polyproteins.
[0072] "Pro" according to the present invention relates also to the
sequence inserted into the deposited MERV-prt plasmid as mentioned
above or a fragment thereof.
[0073] Advantageously, a polynucleotide molecule is provided which
comprises a sequence which is complementary to one of the above
mentioned sequences according to the present invention. Therefore,
not only the sequence according to the RNA strand present in the
retrovirus particle is provided but also a sequence according to
the cDNA sequence.
[0074] Still preferred, the polynucleotide molecule comprises a
detectable label. In particular if the polynucleotide molecule is a
fragment of the above defined sequence, the polynucleotide molecule
can be used for the detection of infectious HERV in a sample.
[0075] The term "detectable label" relates to any marker well known
in the art, e.g. fluorescent, radioactive, enzymatic or chemical
marker.
[0076] A further aspect of the present invention relates to a
polynucleotide molecule coding for a ribozyme, which comprises two
sections, each of which has a length of at least 10 to 15 base
pairs and which are complementary to specific sequence sections of
said above identified polynucleotide molecule according to the
present invention so that said ribozyme complexes and cuts the mRNA
transcribed by a natural infectious human endogenous retrovirus
DNA. The publication by John M. Burg "Clearing the Way for
Ribozymes" (Nat. Biotechnology 15:414-415 (1997)) relates to the
general mode of function of ribozymes and is included herein by
reference. The ribozyme will recognize the mRNA of infectious HERV
by complementary base pairing with said mRNA. The ribozyme will
then cleave and destroy the RNA in a sequence specific manner
before the HERV is translated. After dissociation from the cleaved
substrate the ribozyme will repeatedly hybridize with specific RNA
molecules and act as specific endonuclease. In general, ribozymes
may specifically be produced for inactivation of a certain mRNA
even if not the entire DNA sequence which codes for the infectious
HERV is known.
[0077] Ribozymes are particularly efficient if the ribosomes move
slowly along the mRNA. In that case it is easier for the ribozyme
to find a ribosome free site on the mRNA. For this slow ribosomes
mutants are also suitable as a system for ribozymes (J. Jayburg
(1997), Nature Biotechnology 414-415). A further possible way is
also to use a varied form of a ribozyme, i.e. a minizyme. Minizymes
are efficient particularly for cleaving larger mRNA molecules. A
minizyme is a hammer head ribozyme which has a short
oligonucleotide linker instead of the stem/loop II. Primer
minizymes are particular efficient (Kuferbara et al. (1998), Nature
Biotechnology 16, 961-965).
[0078] Here again the ribozyme comprises sequence sections which
are complementary to "specific" sequence sections of the above
defined polynucleotide molecule according to the present invention.
It is sufficient if at least one of the two sequence sections is
specific, meaning that this specific sequence section will only
bind to an infectious HERV according to the present invention and
not to already known and described non-infectious HERV sequences.
Preferably, however, both sequence sections are specific for the
above defined polynucleotide molecule according to the present
invention, meaning that both sequence sections bind only infectious
HERV sequences.
[0079] A further aspect of the present invention refers to a primer
pair whereby the primers specifically hybridize to a polynucleotide
molecule according to the present invention for an amplification
reaction of a fragment of said polynucleotide molecule. Here again
the term "specifically" refers to primers which will only bind to
the above defined polynucleotide molecule according to the present
invention and not to any known already described HERV. It is
sufficient, if only one of the primers is specific for the
inventive polynucleotide molecule, however, preferably both primers
bind specifically only to the inventive HERV polynucleotide
molecule. This primer pair can be used for any detection reaction
in order to detect the presence of a HERV in a sample, whereby the
term "amplification reaction" relates to any reaction specifically
amplifying a sequence corresponding to the above described HERV
sequence according to the present invention. This may be, for
example, a conventional PCR as well as RT-PCR which are both well
known to a person skilled in the art. However, the primer pair can
also be used to find further herein not defined parts of the
infectious HERV provirus according to the present invention. The
primer pair can furthermore be used to identify other infectious
HERVs which comprise, at least partly, similar sequences to the
sequence of the infectious HERV according to the present
invention.
[0080] The skilled man in the art easily finds conditions wherein
primers which are specific for the infectious HERV sequences
according to the present invention (which e.g. differ from
sequences of known (non-infectious) HERVs by only 1, 2 or 3
nucleotides) only hybridize or anneal to the sequences of the
infectious HERVs according to the present invention, but not to
e.g. the non-infectious HERV sequences known. Examples for such
specific regions are e.g. the regions covering one or more of the
mutations listed in Table 1. Further examples may be derived by the
skilled man in the art e.g. by comparing the sequences of the
present infectious HERV with the known (non-infectious) HERV-K
sequences (e.g. HERV-K108).
[0081] A further aspect of the present invention relates to a
biologically functional vector comprising a polynucleotide molecule
according to the present invention. The biologically functional
vector will comprise all elements necessary for efficiently
expressing the polynucleotide molecule according to the present
invention whereby these elements, e.g. the promoter will be
selected according to the host into which the functional vector
will be transfected and in which the polynucleotide molecule will
be expressed, e.g. to produce a protein or polypeptide encoded by
the present infectious HERV sequences. A person skilled in the art
can select the optimal biologically functional vector without undue
burden.
[0082] Still preferred, a biologically functional vector comprising
a polynucleotide molecule as defined above according to the present
invention in inverse orientation with respect to the promoter is
provided. This vector allows the production of antisense mRNA which
is complementary to the mRNA of the infectious HERV according to
the present invention. The antisense mRNA will bind to the
respective region of the infectious HERV mRNA and therefore block
any further translation and production of viral proteins and
therefore infectious viral particles. Hereby it is sufficient, if
an essential part of the infectious HERV mRNA is blocked in order
to block the production of a complete infectious viral particle,
e.g. part of the gag, pol, pro or env mRNA. Therefore, said
biologically functional vector can be used in cell cultures to stop
the viral production as well as a gene therapy against or
prevention of viral replication in a patient.
[0083] A further aspect of the present invention relates to a
recombinant host cell stably transfected with said biologically
functional vector according to the present invention as defined
above. Here, the person skilled in the art will select the vector
and host cell in order to achieve an effective result, e.g. high
expression of the infectious HERV or fragments thereof.
Transfection methods in order to produce a recombinant host cell
are well known to the person skilled in the art and may comprise
any electroporation, lipofectamin transfection, salt transfection
etc. Depending on the vector which is transfected into the host
cell, the host cell will either express viral peptides, proteins or
particles or produce antisense mRNA.
[0084] Still preferred the host cell is a mammalian cell. This will
allow the production of infectious HERV proteins or peptides with
correct post-translational modifications. The mammalian cell may
be, for example, from any human cell line.
[0085] A further aspect of the present invention relates to a
method for producing an infectious human endogenous retrovirus or
at least one fragment thereof comprising the steps of
[0086] (a) transfecting a host cell with a vector as defined above
according to the present invention,
[0087] (b) selecting and cultivating cells which are stably
transfected with said vector and
[0088] (c) isolating and purifying said retrovirus or said
fragment.
[0089] Here again the above mentioned definitions and preferred
embodiments apply, in particular with respect to the transfection
step and the selection of the host cell and vector. The selection
of stably transfected cells may be carried out according to any
method well known in the art, e.g. selection with antibiotic
resistance or optical selection. The term "fragment" relates to any
peptide encoded by the above defined polynucleotide molecule
according to the present invention. However, the fragment will
preferably refer to a peptide which can be used as an antigen. To
detect fragments which can be used as antigens known homologous
fragments of corresponding HERVs or ERVs can be used, however, such
fragments can also be detected by providing a sample of antibodies
of infectious HERV, which sample can be taken of an infected
patient, incubating said antibody or antibodies with one or more
fragments of the infectious HERV proteins in conditions so that a
binding between corresponding antigens and antibodies occur and
identifying the respective fragments which have bound to antibodies
of infectious HERV.
[0090] A further aspect of the present invention relates to an
infectious human endogenous retrovirus comprising as RNA a
polynucleotide molecule according to the present invention.
Preferably the infectious HERV according to the present invention
will comprise the complete polynucleotide molecule, e.g. comprising
the pol, env, gag, pro genes as well as LTR sequences. However, it
is also possible that the RNA comprises only one or a few, but not
all of the above mentioned genes. It is important that the HERV is
able to carry out a complete retroviral replication cycle and
infect further cells.
[0091] Furthermore, an infectious human endogenous retrovirus is
provided being encoded by a polynucleotide molecule as defined
above according to the present invention.
[0092] A further aspect of the present invention relates to a
preparation comprising an infectious HERV according to the present
invention. The preparation may be a pharmaceutical preparation in
which case preferably a pharmaceutically acceptable carrier is
provided. However, the preparation may also be designed for
diagnostic purposes as well as analytical or other purposes, e.g.
to produce antibodies, to study the effects in animals etc. Of
course, the preparation according to the present invention will
comprise any additional substances depending on the use of the
preparation. The preparation may comprise further virus particles,
as non-infectious HERVs. However, at least one infectious HERV
according to the present invention or a significant portion of the
preparation leading to the overall infectivity of this preparation
must be present.
[0093] A further aspect of the present invention relates to an env
protein, a pol protein, a gag, a pro protein encoded by a
polynucleotide molecule as defined above according to the present
invention. These proteins can be used for any analytical,
diagnostic or production methods and they will be provided in any
form, e.g. with additional substances, depending on the use of the
protein.
[0094] Furthermore a peptide is provided which is a specific
fragment of said retrovirus as defined above according to the
present invention. Here again, "specific" refers to any fragment
which is not identical to a non-infectious HERV fragment already
known. As mentioned above already the fragment may be any fragment
of said retrovirus particle, however, preferably said fragment can
be used as an antigen (e.g. a T or B cell epitope) and therefore be
used in diagnostic methods as well as for the induction of the
production of respective antibodies in a patient or animal and/or
for the induction of specific T cell responses, both TH1 and TH2.
The detection of such fragments can be carried out as described
above.
[0095] The following fragments are examples of such antigens:
[0096] Fragments of the gag protein may be: TABLE-US-00003
LMQNEAIEQVRAICL, (SEQ ID NO:9) IPYDWEILAKSSLSP, (SEQ ID NO:10)
ADQLLGIGQNWSTIS, (SEQ ID NO:11) TISQQALMQNEAIEQ, (SEQ ID NO:12)
EKARKVIVELMAYEN, (SEQ ID NO:13) MAYENANPECQSAIK, (SEQ ID NO:14)
PVLNKQNITIQATTT, (SEQ ID NO:15) RSKFDKNGQPLSGNE, (SEQ ID NO:16)
LSGNEQRGQPQAPQQ, (SEQ ID NO:17) QPPLSQVFQGISQLP, (SEQ ID NO:18)
EIIDKSRKEGDTEAW, (SEQ ID NO:19) VSTKNLIKL, (SEQ ID NO:20)
GIGQNWSTI, (SEQ ID NO:21) QYGPNSPYM, (SEQ ID NO:22) CPVLNKQNI, (SEQ
ID NO:23) LTVWNDWAI, (SEQ ID NO:24) KFDKNGQPL, (SEQ ID NO:25)
GKCYNCGQI, (SEQ ID NO:26) HLKKNCPVL, (SEQ ID NO:27) GRKGNIIPL, (SEQ
ID NO:28) FSIKMLKDM (SEQ ID NO:29)
[0097] Fragments of the env protein may be: TABLE-US-00004
PAVDSDLTESLDKHK, (SEQ ID NO:30) WNSQSSIDQKLANQI, (SEQ ID NO:31)
VSMDRPWEASPSVHI, (SEQ ID NO:32) PAVQNWLVEVPTVSP, (SEQ ID NO:33)
LRPRVNYLQDFSYQR, (SEQ ID NO:34) NTEVLVWEECVANSA, (SEQ ID NO:35)
SAVILQNNEFGTIID, (SEQ ID NO:36) QFYHNCSGQTQSCPS, (SEQ ID NO:37)
NRSKRFIFTLIAVIM, (SEQ ID NO:38) PYMLVVGNI, (SEQ ID NO:39)
IFKASKAHL, (SEQ ID NO:40) KTIGSTTII, (SEQ ID NO:41) GYHYPPICL, (SEQ
ID NO:42) SYQRSLKFR, (SEQ ID NO:43) KGKPCPKEI, (SEQ ID NO:44)
VEVPTVSPI, (SEQ ID NO:45) SLRPRVNYL, (SEQ ID NO:46) TFNWQHRIL (SEQ
ID NO:47)
[0098] Preferably, such peptide fragments contain at least 6 amino
acid residues with at least one residue being specific for the
present infectious HERV sequences, especially at least one of the
amino acid residues not being present in the (non-infectious)
HERV-K (HERV-K108). More preferred these peptides have a length
from 7 to 15 amino acids, especially from 8 to 11. Such peptide
fragments of these lengths are preferably fragments of the above
mentioned gag and env fragments.
[0099] A further aspect of the present invention relates to an
antibody which is directed against an antigen derived from said
retrovirus as defined above according to the present invention. The
production of antibodies towards any specific antigen may be
carried out according to any method well known in the state of the
art, e.g. by immunization of an animal and producing the antibodies
in cell culture. The term "antibody" refers to any form of
antibody, e.g. monoclonal, polyclonal, humanized antibody etc. The
antibodies directed against antigens from the infectious HERV
according to the present invention can be used in immunizing
methods, diagnostic methods or therapeutic methods.
[0100] Preferably, an antibody fragment is provided which is
directed against an antigen derived from said retrovirus as defined
above according to the present invention. Such antibody fragments
may be for example Fa, F(ab).sup.2 or Fv which are capable of
binding an epitopic determinant. Furthermore, single chain
antibodies are comprised by the term "antibody fragment". These
antibody fragments can be used as described above for the
antibodies, however, due to their smaller size they may show
advantages with respect to stability, production etc. Also here,
the antibody fragment is specific, meaning that the antibody
fragment comprises a sequence specific to infectious HERV according
to the present invention.
[0101] A further aspect of the present invention relates to a solid
support which has attached to its surface said antibodies defined
above according to the present invention or said antibody fragments
as defined above according to the present invention. The solid
support according to the present invention may be of any size or
shape, e.g. in the form of a flat slide, microtiter plate, chip,
filter, column, membrane etc. and may be made of any material
generally used for solid supports, e.g. modified or unmodified
glass, polymeric material etc. Hereby the antibody or antibody
fragment can be attached to the complete surface of the solid
support. However, it may also be attached in localized regions, as
for example spots. Also the quantity in which the antibody is bound
to said solid support may vary according to the size of the
antibody or antibody fragment. Of course, for high throughput
assays it will be advantageous to use micro array chips on which
the antibodies or antibody fragments are bound in high density. The
selection of the solid support and the mode of attachment of the
antibody to its surface will depend on the use of said solid
support, e.g. for preparation, purification methods, detection
methods, etc. and a person skilled in the art will be able to
select the most appropriate solid support and the optimum mode of
attachment of said antibody or antibody fragment to said solid
support.
[0102] A further aspect of the present invention relates to a
method for diagnosing cancerous cells comprising the steps of
[0103] (a) providing a sample of said cells to be tested or
supernatant thereof,
[0104] (b) analyzing whether or not said infectious endogenous
retrovirus according to the present invention as described above or
fragment thereof is present in said sample whereby
[0105] (c) the presence of said retrovirus or fragment thereof in
said sample diagnoses cancerous cells.
[0106] The term "cancerous cells" refers to malignant tumor cells.
It has been surprisingly found that the infectious HERV according
to the present invention is related to the transformation of cells
into cancerous cells, especially melanomas. Therefore, by detecting
the presence of said infectious HERV it is possible to diagnose
cancerous cells already at a very early stage. Therefore, the term
"diagnosing cancerous cells" includes also diagnosing cells which
will be transformed into cancerous cells, however, with
conventional methods these cells would not yet be diagnosed as
transformed.
[0107] However, it is not necessary to detect the complete
infectious endogenous retrovirus. It is sufficient to detect at
least one specific fragment thereof. Here again, the term
"specific" refers to a fragment containing a sequence which differs
from the sequences of the known non-infectious HERVs. The detection
method may be carried out according to any protocol known in the
art whereby it is possible to detect said infectious HERV or
fragment thereof on DNA, RNA or protein level. It is further
possible to determine the stage of cancer by determining the amount
of infectious HERV.
[0108] Preferably, said analyzing step comprises an
antigen-antibody reaction using an antibody or antibody fragment as
defined above according to the present invention in order to detect
proteins or protein fragments of said retrovirus. Here, any known
antigen-antibody reaction may be carried out, e.g. on solid
support, in liquid phase, by sandwich-ELISA, etc. It is, of course,
possible to detect antibodies in said sample, however, since the
production of antibodies may vary, it is preferred to detect an
antigen in said sample by providing one or more specific antibodies
whereby these antibodies may be bound to a solid support and/or
comprise a label which may be detected and quantified.
[0109] According to a preferred method said analyzing step
comprises detecting the polynucleotide sequence of said retrovirus
and a fragment of the polynucleotide sequence specific for said
retrovirus, respectively, whereby a hybridization reaction or
amplification reaction is carried out using a polynucleotide as
defined above according to the present invention. Hereby, the term
"polynucleotide sequence" comprises RNA sequences, e.g. the
polynucleotide molecule derived from the transcription of the
respective DNA or the polynucleotide molecule present in the virus
particle, as well as DNA, e.g. cDNA resulting from the reverse
transcriptase reaction thereafter, whereby the cDNA may be still
present in the virus particle or also the DNA already integrated
into the host DNA. Therefore, said amplification reaction will
comprise PCR as well as RT-PCR. Therefore, the above mentioned
primer pair will preferably be used.
[0110] Advantageously, said polynucleotide sequence is transformed
into cDNA in a reverse transcription step prior to said
hybridization step and amplification reaction, respectively. Said
hybridization step will be preferably carried out with one of the
above defined fragments of said polynucleotide molecule according
to the present invention as mentioned above. Hereby it is, of
course, possible to use labeled fragments or labeled nucleotides,
e.g. retroactive nucleotides in order to easily detect and
quantify, respectively, said polynucleotide sequence.
[0111] According to a further preferred method said analyzing step
comprises
[0112] a) providing cells devoid of said endogenous retrovirus,
[0113] (b) adding said supernatant of said sample to said
cells,
[0114] (c) cultivating said cells and
[0115] (d) detecting a polynucleotide molecule as defined above
according to the present invention in the DNA of said cells.
[0116] Since the HERV according to the present invention is
infectious, the supernatant of said sample--if it comprises an
infectious HERV--will infect the cells devoid of said endogenous
retrovirus. After infection the infectious HERVs will integrate
into said cells and further HERV particles will be produced. After
cultivating said cells, therefore, the integrated polynucleotide
molecule of the infectious HERV as defined above will be detectable
in the DNA of said cells. This is a very reliable and quick method
for detecting infectious HERVs. Again, the detection of said
polynucleotide molecule may be carried out by a hybridization step
and amplification reaction, respectively.
[0117] Preferably said cells are non-human cells. Since non-human
cells do not comprise HERVs, the detection of a HERV polynucleotide
molecule in said human cells will be a clear method of detecting
infectious HERV particles. Preferably, said non-human cells are
bovine cells. Infectivity of the virus particles with respect to
these non-human cells is also a way of defining infectivity
according to the present invention.
[0118] Still preferred said sample is a skin tissue sample from a
patient. Since said infectious HERVs preferably infect skin tissue
cells, a sample of a skin tissue is preferably used in order to
detect said infectious HERVs.
[0119] Still preferred, said sample comprises melanocytes. Since
said infectious HERVs are related to cancerous cells a sample
comprising melanocytes is a preferred sample for detecting
infectious HERVs according to the present invention.
[0120] According to a preferred embodiment of the present invention
a method is provided for diagnosing cancer in a patient comprising
the steps of
[0121] (a) providing a sample of said patient to be tested,
[0122] (b) analyzing whether or not at least one antibody as
defined above or antibody fragment as defined above according to
the present invention is present in said sample whereby
[0123] (c) the presence of said antibody or fragment thereof in
said sample diagnoses cancer.
[0124] Here again, the same definitions and preferred embodiments
as mentioned above apply.
[0125] Preferably said sample is a blood sample of said patient. A
blood sample is very easily and quickly taken from a patient
without necessity of costly apparatuses.
[0126] Furthermore, it is possible to diagnose an unlimited amount
of samples in a very short time. As mentioned above for high
throughput assays it is preferable to use microarrays.
[0127] According to an advantageous method said analyzing step
comprises an antigen-antibody reaction using an antigen derived
from said retrovirus as defined above according to the present
invention. Here again, the above mentioned definitions and
preferred embodiments apply.
[0128] According to a further advantageous embodiment a kit is
provided for diagnosing cancerous cells according to the method as
mentioned above according to the present invention comprising
[0129] (a) a first reagent comprising a polynucleotide molecule as
defined above according to the present invention, an antibody as
defined above according to the present invention or an antibody
fragment as defined above according to the present invention or a
solid support as defined above according to the present invention
and
[0130] (b) as a positive control a second reagent comprising a
polynucleotide comprising a sequence which is complementary to the
sequence of said polynucleotide in said first reagent or a
retrovirus as defined above according to the present invention, an
env protein as defined above according to the present invention, a
pol protein as defined above, a gag protein as defined above or a
peptide as defined above according to the present invention. Here
again, the same definitions and preferred embodiments as described
above apply. Of course, it is also possible to provide additionally
to the first reagent a further solid support without attached
antibodies or antibody fragments. In this case the antibody or
antibody fragment as well as the mode of attachment can be
varied.
[0131] According to a further embodiment of the present invention a
kit for carrying out a method for diagnosing cancer in a patient as
described above is provided comprising
[0132] (a) a first reagent comprising an antigen derived from said
retrovirus as defined above and
[0133] (b) as a positive control a second reagent comprising an
antibody according to the present invention or an antibody fragment
as defined above specific for said antigen in said first
reagent.
[0134] Here again the same definitions and preferred embodiments as
described above apply.
[0135] Preferably, said antigen is labeled with a detectable
marker. This marker may be for example radioactive, fluorescent, an
enzymatically or chemically detectable marker.
[0136] Such markers are well known in the state of the art and the
person skilled in the art will be able to select the optimal
marker.
[0137] Still preferred, said antigen is immobilized to a solid
support. This allows an easy handling of said kit and the method
can be carried out immediately without prior preparations.
[0138] According to a further embodiment of the present invention a
PNA molecule is provided which comprises a base sequence
complementary to the sequence of said polynucleotide molecule as
defined above according to the present invention. PNA (peptide
nucleic acid) is a DNA like sequence, the nucleic basis being bound
to a pseudo peptide backbone. PNA generally hybridizes with
complementary DNA, RNA or DNA polymers by Watson-Creek base pair
and helix formation. The peptide backbone ensures a greater
resistance to enzymatic degradation. The PNA molecule thus is an
improved antisense agent.
[0139] Here, the advantage lies in that neither nucleases nor
proteases are capable of attacking a PNA molecule. Therefore, the
PNA molecule is highly stable, if it is bound to a complementary
sequence, since it comprises a sufficient steric blocking of DNA
and RNA polymerases, reverse transcriptase, telemorase and
ribosomes (Buga et al, "Cell Penetrating DNA Constructs Regulate
Alanin Receptor Levels and Modify Transmission in vivo", Nature
Biotechnology 16:857-861 (1998)).
[0140] As in the case of the antisense RNA, if the PNA molecule
comprises the above defined sequence it will bind to the DNA/RNA or
to a site of the DNA/RNA respectively, which codes for infectious
HERV peptides. In this way, the PNA molecule will inhibit the
transcription of the virus. The PNA molecule is prepared
synthetically, e.g. by aid of the T-boc technique, since it is
neither transcribed nor translated.
[0141] The present invention also relates to the use of
anti-retroviral substances for preparing a medicament to treat
melanoma. The present invention therefore provides a method for
treating patients having or being at risk of developing melanoma
comprising administering an effective amount of substances acting
against retroviruses, e.g. substances which inhibit replication and
polymerization of retroviral (infectious HERV) genomes. Examples of
such treatment are e.g. known for the treatment of HIV
infections.
[0142] Preferably, a pharmaceutical composition is provided
comprising a polynucleotide as defined above according to the
present invention, a vector as defined above according to the
present invention, an antibody as defined above, an antibody
fragment as defined above and a PNA molecule as defined above,
respectively, and a pharmaceutically acceptable carrier. Of course,
the pharmaceutical composition may comprise any further molecules
or substances useful for a therapeutic method. The pharmaceutical
composition may for example be provided as a skin cream or lotion,
which may for example be used as an after sun lotion in a
preventive manner.
[0143] Preferably, the pharmaceutical composition further comprises
at least one antiviral substance, especially anti-retroviral
substances. These may be any substances well known in the art, for
example the agents used in known triple anti-retroviral therapy,
see for example Bartlett J A, DeMasi R, Quinn J, Moxham C, Rousseau
F. Overview of the effectiveness of triple combination therapy in
antiretroviral-naive HIV-1 infected adults. AIDS. 2001 Jul
27;15(11):1369-77; Marimoutou C, Chene G, Mercie P, Neau D, Farbos
S, Morlat P, Ceccaldi J, Dabis F. Prognostic factors of combined
viral load and CD4+ cell count responses under triple
antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir
Immune Defic Syndr. 2001 Jun 1;27(2):161-7, which are incorporated
herein by reference.
[0144] According to a further embodiment of the present invention a
sun cream is provided which comprises a polynucleotide as defined
above according to the present invention, an antibody, an antibody
fragment as defined above and a PNA molecule as defined above,
respectively, and at least one UV-protection substance. Therefore,
applying a sun cream with these substances will prevent or inhibit
the production of or infection by infectious HERV according to the
present invention.
[0145] Preferably, said sun cream further comprises at least one
antiviral substance. Here, the same antiviral substance as
mentioned above for the pharmaceutical composition will be
preferred.
[0146] According to a further embodiment of the present invention a
vaccine is provided which comprises as an antigen an attenuated
retrovirus as mentioned above, an env protein, a pol protein, a gag
protein or a peptide as defined above according to the present
invention, respectively, and optionally an adjuvant. Such a vaccine
when applied to a patient will induce the production of antibodies
and/or T cells, which can inhibit infectious HERVs according to the
present invention. Therefore, such a vaccine is a highly effective
substance for treating infectious HERV infections. The production
of vaccines against retroviruses is described in "Hyperattenuated
Recombinant Influenza A Virus Nonstructural-Protein-Encoding
Vectors Induce Human Immunodeficiency Virus Type 1 Nef-Specific
Systemic and Mucosal Immune Responses in Mice", Boris Ferko, Jana
Stasakova, Sabine Sereinig, Julia Romanova, Dietmar Katinger,
Brigitte Niebler, Hermann Katinger, and Andrej Egorov. Journal of
Virology, October 2001, p. 8899-8908, Vol. 75, No. 19, which is
incorporated herein by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0147] The present invention is described in more detail with the
help of the following examples and figures to which it should not,
however, be limited.
[0148] In the drawings:
[0149] FIG. 1 shows the characterization of particle preparations
from melanoma cell supernatants.
[0150] FIG. 2 shows an electron microscopy of melanoma cell-derived
supernatants.
[0151] FIG. 3 shows the expression of the retroviralpol gene in
melanomas.
[0152] FIGS. 4A and 4B show an immunofluorescence analysis with
HERV-K-specific antibodies against gag, cORF, and env.
[0153] FIG. 5 shows cells infected with melanoma-associated
particles.
[0154] FIG. 6 shows the detection of particle associated RNA and
supernatants from infected MDBK cells.
[0155] FIGS. 7A and 7B show the transfer of supernatants from
melanoma particle exposed MDBK cells to uninfected MDBK cells.
[0156] FIGS. 8A and 8B show the vector pCR4Topo (SEQ ID NOs:48 and
49) as well as the gag (SEQ ID NO:50), prot (SEQ ID NO:51), pol
(SEQ ID NO:52) and env (SEQ ID NO:53) primers.
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
EXAMPLES
Example 1
Human Melanoma Cells Contain RT Activity in their Supernatants
[0157] To detect extracellular virions, supernatants from the
melanoma cell lines SKMel-28, SKMel-1, 518A2 were analyzed, as well
as primary melanoma cells for pelletable RT. Supernatants from
cultured human neonatal melanocytes (NHEM) served as controls.
Cell-free supernatants from approximately 10.sup.6 cells were
concentrated by centrifugation. The RT activity of the resulting
pellets was analyzed by F-PERT assay.
[0158] Supernatants from melanoma cell lines, and normal human
melanocytes were centrifuged at 3000.times.g at 4.degree. C. and
sterile-filtered through a 0.22 .mu.m low-protein membrane (Nunc)
to remove cells and cellular debris. The clarified supernatants
were centrifuged for 20 min at 250000.times.g at 4.degree. C. in a
Beckman SW50.1 rotor. Pellets were rinsed with phosphate-buffered
saline (PBS) and centrifuged for 15 min at 250000.times.g and
resuspended. The resulting particle suspensions were used as an
enzyme source for RT assays.
[0159] Pelleted particles derived from 4 ml cell-free supernatants
of approximately 10.sup.6 cells were analyzed. RT activity was
determined by fluorescent probe-based product enhanced RT (F-PERT)
assay as described, with modifications. First, pellets were
suspended in lysis buffer (Roche). Then RT was performed, using the
suspended pellet as source of enzyme, the primer 3'A10
(5'-CACAGGTCAAACCGCCTAGGAATG-3' (SEQ ID NO:54)), and 0.3 .mu.g
MS2-RNA as a template (Roche # 165948). To limit unspecific reverse
transcription, 0.5 .mu.g calf-thymus DNA (Sigma # D4522) was added.
After incubation at 42.degree. C. for 1 h, a 5 .mu.l aliquot of
this reaction was amplified by real-time PCR, by adding 25 .mu.l
TaqMan Universal PCR Master Mix (Applied Biosystems # 4304437), 1
.mu.l of the primers 3'A10 and 5'A 11 (5'-TCCTGCTCAACTTCCTGTCGAG-3'
(SEQ ID NO:55)) at a concentration of 10 .mu.M each, 1 .mu.l F-PERT
probe (genxpress, 10 .mu.M,
5'(FAM)-TCTTTAGCGAGACGCTACCATGGCTA-(TAMRA)3' (SEQ ID NO:56)), and
17 .mu.l AD. The resulting mixture was then amplified by incubating
10 mins at 95.degree. C., followed by 40 cycles at 94.degree. C.
for 20 sec and 64.degree. C. for 1 min, in a SD 7700 (Perkin
Elmer). The calibration curve was generated by plotting the RT
activity of a serial dilution of Moloney Murine Leukemia Virus
(M-MLV) RT (Superscript II Gibco # 18064-014). Alternatively,
detection of reverse transcriptase was performed with a
commercially available reverse transcription assay (Boehringer
Mannheim). In this procedure, dioxigenin (DIG) and biotin-labeled
nucleotides synthesized by the reverse transcriptase are
incorporated into the DNA molecule. Biotion-labeled DNA is then
captured to the streptavidin coated surface of the microtiter
plates. In a subsequent step, an antibody to DIG conjugated to
peroxidase is bound to the dioxigenin-labeled DNA. In the final
step, the peroxidase substrate ABTS and a substrate enhancer were
added. The absorbance of the samples was determined using a
microtiter plate reader. The calibration curve was generated by
plotting a serial dilution of an HIV-1 derived RT with defined
activity.
[0160] Supernatants were found to contain a fluctuating yet
continuously present RT activity, corresponding to the activity of
up to 10000 .mu.units of M-MLV RT (Superscript II, Gibco) per ml
supernatant. On the other hand, supernatants from cultured
melanocytes did not contain detectable RT activity (detection limit
10.sup.-1 .mu.units). The fact that supernatants derived from
melanoma cells but not from melanocytes contain pelletable RT
activity shows that melanoma cells contain proviral sequences with
sufficient genetic information to form particles containing a
functional RT. Since no RT activity was detected in the
supernatants of melanocytes, production of particles containing RT
appears to be activated during transformation of melanocytes to
malignant cells.
Example 2
Human Melanoma Cell Derived Particles Package Sequences with High
Homology to HERV-K
[0161] Retroviral pol genes are generally the most conserved
sequences among retroviruses. In an attempt to analyze the particle
preparations on a molecular level, a sequence was amplified by
using degenerate primers corresponding to conserved sequences of
the pol gene. Particle preparations of the melanoma cell line 518A2
and SK-Mel28 were used for RT-PCR analysis. Particles were treated
with DNase, to remove contaminating traces of genomic DNA.
[0162] Oligonucleotide primers 3'ABDPOLS
5'dCATTCCTTGTGGTAAAACTTTCCA[T/C]TG 3' (SEQ ID NO:57) and 5'ABDPOLAS
5'dCCCCTTGGAATACTCCTGTTTT[T/C]TG 3' (SEQ ID NO:58) (Codon Genetic
Systems, Austria), derived from conserved regions within the
retroviral reverse transcriptase (RT), were adopted from Medstrand
and Blomberg. In order to release viral RNA, the particle
suspension was transferred to a 0.5 ml polypropylene
microcentrifuge tube (Sorensen Inc., USA). Then 10 .mu.l of sterile
water containing 0.1% Triton X-100 and 10 U RNase inhibitor (Gibco)
was added and incubated at 65.degree. C. for 10 min. The reverse
transcription was performed in the same tubes. A mixture containing
50 mM Tris-HCl buffer pH 8.3, 50 mM KCl, 7.5 mM MgCl.sub.2, 5 mM
DTT, 1 mM dNTPs, 20 pmol primer 3'ABDPOLA, 10 U RNase inhibitor and
100 U of Superscript II RT (Gibco) in a final volume of 20 .mu.l
was added while the tubes were kept on ice. The reaction was
performed at 42.degree. C. for 45 min.
[0163] For PCR, the reaction mixture contained 10 mM Tris-HCl
buffer pH 8.3, 50 mM KCl, 1.5 mM MgCl.sub.2, 0.005% (w/v) gelatin,
0.2 mM dNTPs, 25 pmol of 3'ABDPOLS and 5'ABDPOLAS, 10 .mu.l of the
reverse transcription reaction and 1.25 U Taq polymerase
(Boehringer Mannheim) in a final volume of 50 .mu.l. The reaction
mixes were overlaid with mineral oil and subjected to 3 thermal
cycles of denaturation at 92.degree. C. for 45 s, primer annealing
at 45.degree. C. for 45 s and elongation at 72.degree. C. for 60 s,
followed by 45 cycles at 92.degree. C. for 45 s, 55.degree. C. for
45 s and 72.degree. C. for 60 s. 10 .mu.l of each amplification
product were analyzed by electrophoresis in a 1.5% agarose gel and
visualized by ethidium bromide staining. An aliquot of the
amplification product was cloned and sequenced.
[0164] RT-PCR of these preparations revealed the anticipated
amplification products of 298 nucleotides. Since no amplification
products were obtained when RT was omitted, possible DNA
contaminations can be excluded (FIG. 1a). (A) RT-PCR. Particle
preparations of the melanoma cell line Mel-Juso were treated with
DNase and used for analysis. PCR (lane 1) or RT-PCR (lane 2) with
degenerate primers corresponding to sequences that are conserved in
retroviral polymerase (pol) genes was performed; M, molecular
weight marker (Boehringer Mannheim VIII). No amplification products
were obtained in the control reactions without RT, demonstrating
the absence of contamination with DNA (lane 1). In contrast, RT-PCR
revealed the anticipated amplification products of 298 nucleotides
(lane 2). (B) Immunoblotting. Particle preparations from SK-Mel28
supernatants were separated by SDS-PAGE, blotted and
HERV-K-specific proteins were detected with antiserum recognizing
env (lane 1), gag (lane 3) and the corresponding pre-immunesera,
pre-env (lane 2) and pre-gag (lane 4). Molecular weight is
indicated to the left. In addition, RT-PCR of the GAPDH gene was
negative, reflecting the lack of contamination with cellular mRNA
(data not shown). The amplification product was cloned into an
expression vector and sequenced. Sequence analysis revealed that
the amplified fragment shows high homology to the corresponding pol
region of endogenous retrovirus HERV-K. Translation of the obtained
nucleotide sequence revealed the amino acid sequence
IKKKSGKWRMLTDLRAINSVIQPMGALQPGLPSPAIIPKNWPLVVIDLKDSFFTIPL
ADQDCEWFAFIIPAVNNLQPAKHF (SEQ ID NO:59). This sequence is highly
homologous with the corresponding sequences of the HERV-K HML2 and
HML3 families. Within these groups the highest identity (90%) was
observed for clone NMWV5 (GenBank accession AF0115998). Homology to
sequences of type A, B and C retroviruses was less than 70%. The
sequence analysis excludes contamination with any known non-human
retrovirus and suggests an endogenous origin of the packaged
RNA.
Example 3
Human Melanoma Derived Particles Contain Mature gag and env
Proteins
[0165] Particles derived from SK-Mel28 melanoma cells were purified
on iodixanol-cushions and analyzed for the presence of
HERV-K-specific env and gag proteins in Western blots.
[0166] Iodixanol-cushion purified particles from SK-Mel28
supernatants were pelleted, resuspended in PBS and analyzed. The
amount of soluble proteins was quantified by means of a modified
Bradford analysis (Bio-rad, Richmond Calif.). 5 .mu.g of total
protein was applied per lane and separated by SDS-PAGE (10%).
Proteins were transferred to PVDF membranes (Millipore, Bedford,
Mass.) by Western blotting, and generated blots were incubated with
the gag- and env-specific antisera. The membranes were washed twice
with blocking solution and HERV-K-specific proteins were detected
with an alkaline-phosphatase-conjugated second-step antibody.
[0167] The envelope (env) gene of retroviruses displays an ORF for
the surface protein (SU) and a membrane spanning protein (TM). The
env precursor is usually cleaved into the SU and TM subunits before
translocation to the cell surface and incorporation into virus
particles. To determine whether the env protein is present on the
particles, immunoblotting with an antiserum recognizing the TM
domain was performed. As shown in FIG. 1b two bands are visible in
the Western blot. The upper band corresponds to the precursor
migrating at approximately 80 to 90 kDa. In addition, a lower band
migrating at approximately 37 kDa is visible, suggesting cleavage
of the precursor into subunits.
[0168] Immunoblotting with an HERV-K anti-gag antiserum revealed a
double band at approximately 76 kDa, corresponding to gag
precursors, as well as processed intermediate gag proteins at
approximately 61 kDa, 30 kDa and one band migrating with the front
(less than 19 kDa). The 30 kDa protein corresponds to the putative
major core protein of HERV-K. The presence of processed gag
proteins in the Western blots indicates a functional protease.
Example 4
Human Melanoma Cells Produce Retrovirus-Like Particles
[0169] To confirm the presence of particles electron microscopy
(EM) was performed.
[0170] 15 .mu.l aliquots of iodixanol-density gradient purified
particle suspensions from SK-Mel28 supernatants were applied on
Formvar coated grids and left there for 15 min. Excess suspension
was removed from the edges of the grids by filter paper. The grid
with the remaining sample was air dried for 1 h. The sample was
either directly exposed to 1% uranyl acetate for negative staining
or, for immunoelectron microscopy, fixed in
paraformaldehyde-lysine-periodate for 15 min, rinsed in distilled
water, quenched in PBS/1% BSA and incubated in anti-env antiserum
diluted 1:25 in PBS/1% BSA for 1 h at RT. After washing, the grid
was exposed to 5 nM colloidal gold conjugated rabbit anti-goat
antibody (British Biocell, Cardiff, UK) diluted 1:50 in PBS/1% BSA
for 1 h. After fixation in 2.5% glutaraldehyde, washing and
negative staining with 1% uranyl acetate, the grid was left to air
dry. All grids were examined with a JEOL 1010 electron
microscope.
[0171] For electron microscopy, immunoblotting and infection
studies, cell-free supernatants were purified on iodixanol density
gradients or cushions. Iodixanol is an iodinated, nonionic density
gradient medium (Nycomed Pharma, Oslo, Norway). It has a low
viscosity and provides iso-osmotic conditions up to densities of
1.32 g/ml. The supernatants were overlaid on a cushion of 5 ml 50%
iodixanol. The tubes were centrifuged in an SW28 rotor at
45000.times.g for 2 h at 4.degree. C. and the supernatant was
removed from the tubes by suction, leaving a volume of 4 ml of the
medium in proximity of the cushion. This fraction was harvested,
pelleted in a SW41 rotor at 150000.times.g for 90 min at 4.degree.
C., resuspended in PBS and analyzed. Alternatively, for further
purification the cushion-derived fraction was loaded on iodixanol
density gradients, and the fraction corresponding to a density of
approximately 1.16 g/ml was harvested. The harvested fractions were
diluted in PBS and pelleted in a SW41 rotor at 150000.times.g for
90 min at 4.degree. C. and resuspended in PBS.
[0172] Pellets were partially purified on iodixanol-cushions (FIG.
2, upper part). Alternatively, these fractions were further
purified on iodixanol density-gradients (FIG. 2, lower part). These
preparations were analyzed by immunelectron microscopy using an
env-specific antiserum and a colloidal gold conjugated reporter
antibody. EM analysis of these preparations revealed the presence
of retrovirus-like particles characterized by membrane bound
spherical structures with diameters ranging between 80 and 120 nm.
The presence of immunogold on the particles indicates that the env
protein is present in the envelope.
Example 5
The pol Gene is Expressed in Tumor Cells Derived from Melanomas
[0173] The integration sites of human endogenous retroviral
elements have been found to be distributed over the whole human
genome. For example, the HERV-K family was reported to be present
in approximately 30 copies per human haploid genome. Based on the
observation that melanoma cells (but not melanocytes) produce
retrovirus-like particles, it can be hypothesized that the
formation of virus-like particles might be due to the activation of
retroviral genes that are usually repressed. Therefore the cloned
pol sequence derived from the particle preparations was used as a
probe and looked for expression of this sequence in the cytoplasm
of melanoma cells by in situ hybridization.
[0174] Touch preparations of a nevus, primary melanoma, and
melanoma metastasis were made by dipping freshly excised tissue on
coated slides (DAKO, Biotek Solutions). Slides were fixed in 4%
paraformaldehyde for 20 mins, washed in PBS, dehydrated through
graded alcohols to absolute ethanol, and were air dried.
[0175] The hybridization mixtures consisted of Hybrisol VI (Oncor,
Gaithersburg) and DIG-labeled cDNA probes, giving a final
concentration of 2 ng/.mu.l. Slides were covered with glass
coverslips and sealed with Gelbond (ICN). Probe and cellular
material were denatured by heating to 80.degree. C. for 5 mins.
Hybridization was carried out at 37.degree. C. overnight in a humid
chamber. After removal of the coverslips the slides were washed at
46.degree. C. three times with 50% formamide/2.times.SSC, once with
2.times.SSC for 10 mins, followed by a single wash step in
2.times.SSC containing 0,1% NP40 for 10 mins. Signal detection was
performed after a blocking step in 1% blocking reagent (Boehringer
Mannheim) of 30 mins at 37.degree. C. by incubation with anti-DIG
antibody, conjugated to rhodamine at a dilution of 1:10 in 1%
blocking reagent for 30 mins at 37.degree. C. in a humidified box.
After extensive washings in PBS, slides were counterstained with 10
.mu.g/ml DAPI for 20 mins and visualized with a Zeiss fluorescence
microscope using a triple bandpass filter and software from
PSI.
[0176] To determine the specificity of the pol sequence for
melanoma, touch preparations of a nodular melanoma were analyzed, a
lymph node metastasis, and a cutaneous metastasis that had been
surgically removed from melanoma patients. As shown in FIG. 3
(Touch preparations from primary melanoma (a), lymph node
metastasis (b), cutaneous metastasis (c), nevus (d), and a tumor
free sentinel lymph node (e) surgically removed from patients were
analyzed by in situ hybridization with probes specific for
nucleotide sequences of the pol gene (POL), melanoma inhibiting
activity gene (MIA), and the influenza virus nucleoprotein (FLU).
Nucleotide sequences of the pol and the melanoma inhibiting
activity genes are found in primary melanoma and lymph node and
cutaneous metastases but not in the nevus and tumor free lymph
node), high copy numbers of the pol sequence were found in tumor
cells of all melanoma preparations tested. In comparison, cells
derived from the lymph node and the benign nevus of healthy
individuals were negative. A probe specific for the nucleoprotein
gene of influenza virus was always negative. As a positive control,
a probe recognizing the melanoma-inhibiting activity gene was used.
The rate of tumor cells expressing the pol gene was in the range of
60-90%, a percentage similar to the one obtained with the
melanoma-inhibiting activity specific probe. The observation that
the sequences are not found in all tumor cells might be due to the
sensitivity of the assay and variations in the expression
levels.
Example 6
Retroviral gag, cORF, and env Proteins are Expressed in
Melanomas
[0177] To determine whether HERV-specific proteins were detectable
in melanoma cells, immunofluorescence analysis with antisera
recognizing the gag, cORF and env proteins of HERV-K was
performed.
[0178] Cells grown on chamber slides, as well as touch preparations
from a nevus and primary melanoma on coated slides (DAKO) were
fixed in 4% paraformaldehyde for 20 mins, washed in PBS and
dehydrated through graded alcohols to absolute ethanol and air
dried. In addition, five micrometer sections prepared from
routinely processed paraffin wax blocks of a nevus and melanoma
were placed on coated slides (DAKO). The tissues were dewaxed in
xylene, rehydrated by sequential immersion in graded ethanols and
PBS and subsequently permeabilised by microwave treatment.
[0179] Immunofluorescence staining was performed by incubating
chamber slides, touch preparations, and paraffin sections with
HERV-K-specific antibodies at a dilution of 1:100 for 1 h at
37.degree. C. in a humidified box, followed by washing three times
with PBS and subsequent incubation with Alexafluor-488-conjugated
antibodies at a dilution of 1:200 for 1 h at 37.degree. C.
Counterstaining was performed by mounting in Vectashield containing
DAPI (Vector). Preparations were analyzed by using a Zeiss
fluorescence microscope with appropriate filters.
[0180] FIG. 4a shows that the melanoma cell lines Mel-Juso and
SK-Mel28 express the gag, cORF and env proteins. The percentage of
gag-expressing cells was in the range of 1-10%, cORF was found to
be present in about 20%, while expression of the env protein was
detected in about 10% of the analyzed cells. Expression of gag and
env was found in the cytoplasm, while cORF was mainly found in the
nucleus. In contrast, cultured human melanocytes (Nhem) and Vero
cells did not react with any HERV-K-specific antisera. None of the
corresponding preimmune-sera was reactive with any of the cells
tested. immunofluorescence analysis was performed with touch
preparation of a primary melanoma (first column); touch preparation
of a nevus (second column); paraffin preparation primary melanoma
(third column); paraffin preparation nevus (fourth column).
Retroviral proteins are present in the melanoma preparations but
absent from nevus tissue.
[0181] It was then analyzed whether these proteins are also
expressed in primary melanoma. FIG. 4b shows that gag, cORF, and
env were detected in touch preparations and paraffin sections of a
primary melanoma but not in the corresponding preparations of a
nevus.
Example 7
Melanoma Cell Derived Particles are Infectious
[0182] Supernatants of approximately 108 melanoma cells were loaded
on 30% sucrose cushions and centrifuged at 28K. The resulting
pellets were washed and resuspended in 500 .mu.l PBS. For infection
studies human 293 cells were grown to approximately 30% confluency
and exposed overnight to the particle preparations in the presence
of 8 .mu.g/ml polybrene. As controls, cells were treated with
particle preparations that were heat inactivated 30 min at
60.degree. C. or mock-treated. 293 cells were exposed to particle
preparations from the melanoma cell line SKMe128.
[0183] The human epithelial cell line 293 is a well established
target for retrovirus infection. Immunofluorescence with HERV-K
specific gag antibodies was performed three weeks post infection
(p.i.). Control cells were mock-treated. 293 cells were treated
with the melanoma-derived viral particles, and demonstrate that
upon treatment they express the HERV-K specific gag-protein (FIG.
5a). Moreover, expression of the retroviral proteins correlated
with the level of pelletable RT-activity in the supernatants (FIG.
5b), suggesting that the 293 cells were infected with the
melanoma-derived particles. However, due to the high copy numbers
of various HERV sequences present in the human genome it was not
possible to demonstrate that expression of proteins and production
of RT-containing particles was derived from de novo integrated
retroviral DNA into the hosts genome. Therefore this question was
addressed in bovine MDBK cells.
Example 8
Infection of MDBK Cells
[0184] It was tested whether the melanoma-derived particles are
infectious. Due to the high copy numbers of various HERV sequences
present in the human genome it is difficult to demonstrate in human
cells whether virus particles produced are derived from endogenous
or exogenous virus. This question was therefore addressed in bovine
MDBK cells which are free of viruses that are homologous to HERV-K.
MDBK cells were exposed to melanoma derived particle preparations
and passaged at a ratio of 1:10. Supernatants of these cells were
analyzed by RT-PCR with pol-specific HERV primers as described
below:
[0185] Cell free supernatants of approximately 10.sup.8 518A2
melanoma cells were loaded on 20% sucrose cushions and pelleted at
28K in a Beckmann SW28 rotor. The resulting pellets were washed and
resuspended in 500 .mu.l PBS. For infection studies bovine MDBK
cells were grown to approximately 30% confluency and exposed
overnight to 100 .mu.l aliquots of the particle preparations in the
presence of 0.8% polybrene. As controls, cells were treated with
particle preparations that were heat inactivated. 24 hour post
infection (p.i.) the inoculum was removed, the cells were washed
twice with PBS and incubated with normal media. Starting at 7 days
p.i. the cells were continuously passaged at a ratio of 1:10 and
the supernatants were analyzed for the presence of viral particles
by detecting particle-associated RNA. In addition 1.5 ml of the
supernatants from infected MDBK cells were put onto new
(uninfected) MDBK cells, in the presence of polybrene. 24 hours
later the cells were washed twice with PBS and incubated for 7
days, and passaged at a ratio of 1:10. The release of particles
from the cells was determined by detecting particle-associated RNA
in the supernatants by RT-PCR as described below:
[0186] For detecting particles released by the cells, supernatants
from approximately 10.sup.7 518A2 or infected MDBK cells were
filtered, pelleted 2 hours at 28K and resuspended in 500 .mu.l
Trizol. To this suspension 100 .mu.l chloroform were added. After
vortexing and centrifugation the upper phase was precipitated with
isopropanol. The precipitate was pelleted by centrifugation and
washed with 70% ethanol. The pellet was resuspended, treated with
DNase in the presence of 25 mM MgCl.sub.2 for 45 min at 37.degree.
C., and the DNAse was inactivated for 10 min at 65.degree. C. After
precipitation with 96% ethanol, the pellet was washed with 70%
ethanol, resuspended in reverse transcription (RT) reaction buffer
and RT was performed with the random primer p(dN)6.1/10 of the
reverse transcription reaction was used as template for PCR with
the oligonucleotide primers 5'108 propol 3925 5'
CCACTGTAGAGCCTCCTAAACCC 3' (SEQ ID No 6) and 3'108 pol 4315 5'
GCTGGTATAGTAAAGGCAAATTTTTC 3' (SEQ ID No 7) (Codon Genetic Systems,
Austria) which correspond to conserved regions within the pol
gene.
[0187] 10 .mu.l of each amplification product were analyzed by
electrophoresis in a 1.5% agarose gel and visualized by ethidium
bromide staining. An aliquot of the amplification product was
cloned and sequenced. Expression of HERV-specific RNA expressed in
MDBK cells was detected by RT-PCR of total genomic RNA derived from
approximately 10.sup.7 cells in the same manner.
[0188] FIG. 6 shows the result after the first passage. Lanes 1-6:
After infection cells were passaged 1:10 and supernatants were
analyzed by RT-PCR with pol-specific primers (+). Absence of
contaminating DNA was analyzed by omitting the RT step (-); Lane 1,
no template control; lane 2, heat inactivated particles; lane 3,
particle preparation diluted 1:100, lane 4, 1:10 dilution, lane 5,
undiluted particle preparations; lane 6, 518A2 supernatant; M,
molecular weight marker; Analysis of genomic DNA with pol-specific
primers by PCR. Lane 1, no template control; lane 2, no template
control; lane 3, MDBK DNA; lane 4, 518A2 DNA, lane 5, no enzyme
control. Infection with undiluted particle preparations revealed a
pol-specific amplification product ( lane 5, +), while infection
with particle preparations that were diluted 1:10 (lane 4+),
diluted 1:100 (lane 3+)or were heat inactivated (lane 2+) did not.
None of the reactions revealed a signal when the RT step was
omitted, excluding that the signals were derived from genomic DNAs
contaminations (lanes 2-6,-). The presence of particle associated
viral sequences in the supernatant of the melanoma-derived particle
exposed MDBK cells indicates that melanoma-derived particles are
capable to infect bovine cells.
[0189] Sequence analysis of the amplification product of lane 5
revealed the nucleotide sequence 5 '
CCACTGTAGAGCCTCCTAAACCCATACCATTAACTTGGAAAACAGAAAAAC
CGGTGTGGGTAAATCAGTGGCCGCTACCAAAACAAAAACTGGAGGCTTTACA
TTTATTAGCAAATGAACAGTTAGAAAAGGGTCATATTGAGCCTTCGTTCTCAC
CTTGGAATTCTCCTGTGTTTGTAATTCAGAAGAAATCAGGCAAATGGCATAT
GTTAACTGACTTAAAGGCCGTAAACGCCGTAATTCAACCCAT 3' (SEQ ID No 8). This
sequence is highly homologues (98%) to the sequence from HERV-K
108.
Example 9
Supernatants from Infected MDBK Cells Contain Infectious
Particles
[0190] Cell free supernatants from cells exposed to undiluted
melanoma particle preparations were put onto new (uninfected) MDBK
cells which were subsequently passaged 3 times at a ratio of
1:10
[0191] FIG. 7 shows the transfer of supernatants from
melanoma-particle exposed MDBK cells to uninfected MDBK cells. 24
hours later cells were washed twice with PBS, incubated for one
week, and subsequently passaged at a ratio of 1:10. FIG. 7a shows
pelleted supernatants from these cells which were analyzed for
release of particle-associated RNA by RT-PCR with pol-specific
primers (lanes 1, 3, 5, 7). As negative controls supernatants from
MDBK cells exposed to heat inactivated particles were transferred
to MDBK cells which were treated and analyzed in the same manner
(lanes 2, 4, 6, 8). Lanes 1 and 2: 5 days after transfer; lanes 3
and 4: passage 1; lanes 5 and 6: passage 2; lanes 7 and 8: passage
3; lane M: molecular weight marker (Boehringer Mannheim VIII); lane
9: negative control: pelleted supernatant from uninfected MDBK
cells; lane 10: positive control: pelleted supernatants from 518A2
cells; FIG. 7b shows the expression of HERV-specific RNAs which was
analyzed by RT-PCR from whole genomic RNA of MDBK cells from
passage 1 with pol-specific primers. Lane 1: MDBK cells treated
with supernatants from infected MDBK cells; lane 2: MDBK cells
treated with supernatants from MDBK cells exposed to heat
inactivated melanoma-derived particle preparations; lane M,
molecular weight marker (Boehringer Mannheim VIII); lane 3,
negative control: PCR of genomic DNA derived from uninfected MDBK
cells; lane 4, positive control: PCR of genomic DNA derived from
518A2 cells; lane 5: non-template control. Lanes 1, 3, 5, and 7
correspond to passages 0, 1, 2, and 3 respectively. Lanes 2, 4, 6,
and 8 are the negative controls and correspond to passages 0, 1, 2,
and 3 of cells treated with supernatants from cells exposed to heat
inactivated particle preparations.
[0192] Shown is the presence of particle associated RNA as
indicated by the presence of a pol-specific sequences. Pol-specific
signals were detectable after passages 0, 1, and 3, suggesting the
presence of viral particles (lanes 1, 3, and 7). Analysis of
passage number 2 did not reveal a pol-signal which might be due to
fluctuating production levels of viral particles (lane 5). Transfer
of supernatants from MDBK cells that were treated with heat
inactivated particle preparations did not result in the release of
particles (lanes 2, 4, 6, and 8). PCR alone did not reveal
pol-specific signals, indicating that the signals obtained by
RT-PCR are derived from RNA. The result that transfer of the
supernatant from infected MDBK cells to uninfected MDBK cells
resulted in the release of particle associated viral RNA, indicates
that infection with melanoma derived particles of MDBK cells is
productive.
[0193] These data show that retroviral sequences and infectious
particles are expressed in melanoma cells.
[0194] Partial sequence analysis, immunoblotting and
immuno-electron microscopy studies show the particles belong to the
HERV-K family. In contrast to other known HERV-K like viruses,
which lack infectivity, the env precursor appears to be cleaved in
the melanoma derived particles, resulting in approximately
equimolar amounts of the precursor and the putative transmembrane
domain. Cell-free particle preparations from the melanoma cells
were able to infect both human and bovine cells, as indicated by
the appearance of the viral proteins gag, cORF, and env, and
pelletable RT-activity in the supernatants of infected cells.
Moreover, the fact that human pol and gag sequences in the genome
of the infected bovine MDBK cells were detected, indicates that the
melanoma-associated viruses are capable of de novo integration of
their genome. This observation also suggests the presence of a
functional integrase in the viral particles.
[0195] FIG. 8a shows the pCR4-Topo vector into which the MERV gag,
pro, pol and env sequences isolated from the above described
infected bovine cells were inserted. The primers used in the above
examples are shown in the boxes of each sequence of vectors shown
in FIG. 8b. These vectors were deposited on 26 Sep. 2001 at the
DSMZ under the names MERV-env, MERV-gag, MERV-prt and MERV-pol
according to the Budapest Treaty.
Sequence CWU 1
1
59 1 7475 DNA Human endogenous retrovirus 1 gctagggtga taatggggca
aactaaaagt aaaattaaaa gtaaatatgc ctcttatctc 60 agctttatta
aaattctttt aaaaagaggg ggagttaaag tatctacaaa aaatctaatc 120
aagctatttc aaataataga acaattttgc ccatggtttc cagaacaagg aactttagat
180 ctaaaagatt ggaaaagaat tggtaaggaa ctaaaacaag caggtaggaa
gggtaatatc 240 attccactta cagtatggaa tgattgggcc attattaaag
cagctttaga accatttcaa 300 acagaagaag atagcgtttc agtttctgat
gcccctggaa gctgtataat agattgtaat 360 gaaaacacaa ggaaaaaatc
ccagaaagaa acggaaggtt tacattgcga atatgcagca 420 gagccggtaa
tggctcagtc aacgcaaaat gttgactata atcaattaca ggaggtgata 480
tatcctgaaa cgttaaaatt agaaggaaaa ggtccagaat tagtggggcc atcagagtct
540 aaaccacgag gcacaagtcc tcttccagca ggtcaggtgc ctgtaacatt
acaacctcaa 600 acgcaggtta aagaaaataa gacccaacca ccagtagctt
atcaatactg gccgccggct 660 gaacttcagt atcggccacc cccagaaagt
cagtatggat atccaggaat gcccccagca 720 ccacagggca gggcgccgta
ccctcagccg cccactagga gacttaatcc tacggcacca 780 cctagtagac
agggtagtga actacatgaa attattgata aatcaagaaa ggaaggagat 840
actgaggcat ggcaattccc agtaatgtta gaaccgatgc cacctggaga aggagcccaa
900 gagggagagc ctcccacagt tgaggccaga tacaagtctt tttcaataaa
aatgctaaaa 960 gatatgaaag aaggagtaaa acagtatgga cccaactccc
cttatatgag gacattatta 1020 gattccattg ctcatggaca tagactcatt
ccttatgatt gggagattct ggcaaaatcg 1080 tctctctcac cctctcaatt
tttacaattt aagacttggt ggattgatgg ggtacaagaa 1140 caggtccaaa
gaaatagggc tgccaatcct ccagttaaca tagatgcaga tcaactatta 1200
ggaataggtc aaaattggag tactattagt caacaagcat taatgcaaaa tgaggccatt
1260 gagcaagtta gagctatctg ccttagagcc tgggaaaaaa tccaagaccc
aggaagtacc 1320 tgcccctcat ttaatacagt aagacaaagt tcaaaagagc
cctatcctga ttttgtggca 1380 aggctccaag atgttgctca aaagtcaatt
gccgatgaaa aagcccgtaa ggtcatagtg 1440 gagttgatgg catatgaaaa
cgccaatcct gagtgtcaat cagccattaa gccattaaaa 1500 ggaaaggttc
ctgcaggatc agatgtaatc tcagaatatg taaaagcctg tgatggaatc 1560
ggaggagcta tgcataaagc tatgcttatg gctcaagcaa taacaggagt tgttttagga
1620 ggacaagtta gaacatttgg aggaaaatgt tacaattgtg gtcaaatcgg
tcacttaaaa 1680 aagaattgcc cagtcttaaa caaacagaat ataactattc
aagcaactac aacaggtaga 1740 gagccacctg acttatgtcc aagatgtaaa
aaaggaaaac attgggctag tcaatgtcgt 1800 tctaaatttg ataaaaatgg
gcaaccattg tcgggaaacg agcaaagggg ccagcctcag 1860 gccccacaac
aaactggggc attcccaatt cagccatttg ttcctcaggg ttttcaggga 1920
caacaacccc cactgtccca agtgtttcag ggaataagcc agttaccaca atacaacaat
1980 tgtcccccac cacaagcggc agtgcagcag tagatttatg tactatacaa
gcagtctctc 2040 tgcttccagg ggagccccca caaaaaatcc ccacaggggt
atatggccca ctgcctgaga 2100 ggactgtagg actaatcttg ggaagatcaa
gtctaaatct aaaaggagtt caaattcata 2160 ctggtgtggt tgattcagac
tataaaggcg aaattcagtt ggttattagc tcttcaattc 2220 cttggagtgc
cagtccagga gacaggattg ctgaattatt actcctgcca tatattaagg 2280
gtggaaatag tgaaataaaa agaacaggag ggtttggaag cactgatccg acaggaaagg
2340 ctgcatattg ggcaagtcag gtctcagaga acagacctgt gtgtaaggcc
attattcaag 2400 gaaaacagtt tgaagggttg gtagacactg gagcagatgt
ctctatcatt gctttaaatc 2460 ggtggccaaa aaattggcct aaccaaaagg
ctgttacagg acttgtcggc ataggcacag 2520 cctcagaagt gtatcaaagt
acggagattt tacattgctt agggccagat aatcaagaaa 2580 gtactgttca
gccaatgatt acttcaattc ctcttaatct gtggggtcga gatttattac 2640
aacaatgggg tgcggaaatc accatgcccg ctccatcata tagccccacg agtcaaaaaa
2700 tcatgaccaa gatgggatat ataccaggaa agggactagg gaaaaatgaa
gatggcatta 2760 aaattccagt tgaggctaaa ataaatcaag aaagagaagg
aatagggtat cctttttagg 2820 ggcggccact gtagagcctc ctaaacccat
accattaact tggaaaacag aaaaaccggt 2880 gtgggtaaat cagtggccgc
taccaaaaca aaaactggag gctttacatt tattagcgaa 2940 tgaacagtta
gaaaagggtc atattgagcc ttcattctca ccttggaatt ctcctgtgtt 3000
tgtaattcag aagaaatcag gcaaatggcg tatgttaact gacttaaggg ccgtaaacgc
3060 cgtaattcaa cccatggggc ctctccaacc tgggttgccc tctctggcca
tgatcccaaa 3120 agactggcct ttaattataa ttgatctaaa ggattgcttt
tttaccatcc ctctggcgga 3180 gcaggattgc gaaaaatttg cctttactat
accagccata aataataaag aaccagccac 3240 caggtttcag tggaaagtgt
tacctcaggg aatgcttaat agtccaacta tttgtcagac 3300 ttttgtaggt
cgagctcttc aaccagttag agaaaagttt tcagactgtt atattattca 3360
ttatattgat gatattttat gtgctgcaga aacgaaagat aaattaattg actgttatac
3420 atttctgcaa gcagaggttg ccaatgctgg actggcaata gcatctgata
agatccaaac 3480 ctctactcct tttcattatt tagggatgca gatagaaaat
agaaaaatta agccacaaaa 3540 aatagaaata agaaaagaca cattaaaaac
actaaatgat tttcaaaaat tactaggaga 3600 tattaattgg attcggccaa
ctctaggcat tcctacttat gccatgtcaa atttgttctc 3660 tatcttaaga
ggagactcag acttaaatag taaaagaatg ttaaccccag aggcaacaaa 3720
agaaattaaa ttagtggaag aaaaaattca gtcagcgcaa ataaatagaa tagatccctt
3780 agccccactc caacttttga tttttgccac tgcacattct ccaacaggca
tcattattca 3840 aaatactgat cttgtggagt ggtcattcct tcctcacagt
acagttaaga cttttacatt 3900 gtacttggat caaatagcta cattaatcgg
tcagacaaga ttacgaataa taaaattatg 3960 tgggaatgac ccagacaaaa
tagttgtccc tttaaccaag gaacaagtta gacaagcctt 4020 tatcaattct
ggtgcatgga agattggtct tgctaatttt gtgggaatta ttgataatca 4080
ttacccaaaa acaaagatct tccagttctt aaaattgact acttggattc tacctaaaat
4140 taccagacgt gaacctttag aaaatgctct aacagtattt actgatggtt
ccagcaatgg 4200 aaaagcagct tacacaggac cgaaagaacg agtaatcaaa
actccatatc aatcggctca 4260 aagagcagag ttggttgcag tcattacagt
gttacaagat tttgaccaac ctatcaatat 4320 tatatcagat tctgcatatg
tagtacaggc tacaagggat gttgagacag ctctaattaa 4380 atatagcatg
gatgatcagt taaaccagct attcaattta ttacaacaaa ctgtaagaaa 4440
aagaaatttc ccattttata ttacacatat tcgagcacac actaatttac cagggccttt
4500 gactaaagca aatgaacaag ctgacttact ggtatcatct gcactcataa
aagcacaaga 4560 acttcatgct ttgactcatg taaatgcagc aggattaaaa
aacaaatttg atgtcacatg 4620 gaaacaggca aaagatattg tacaacattg
cacccagtgt caagtcttac acctgcccac 4680 tcaagaggca ggagttaatc
ccagaggtct gtgtcctaat gcattatggc aaatggatgt 4740 cacgcatgta
ccttcatttg gaagattatc atatgttcac gtaacagttg atacttattc 4800
acatttcata tgggcaactt gccaaacagg agaaagtact tcccatgtta aaaaacattt
4860 attgtcttgt tttgctgtaa tgggagttcc agaaaaaatc aaaactgaca
atggaccagg 4920 atattgtagt aaagctttcc aaaaattctt aagtcagtgg
aaaatttcac atacaacagg 4980 aattccttat aattcccaag gacaggccat
agttgaaaga actaatagaa cactcaaaac 5040 tcaattagtt aaacaaaaag
aagggggaga cagtaaggag tgtaccactc ctcagatgca 5100 acttaatcta
gcactctata ctttaaattt tttaaacatt tatagaaatc agactactac 5160
ttctgcagaa caacatctta ctggtaaaaa gaacagccca catgaaggaa aactaatttg
5220 gtggaaagat aataaaaata agacatggga aatagggaag gtgataacgt
gggggagagg 5280 ttttgcttgt gtttcaccag gagaaaatca gcttcctgtt
tggataccca ctagacattt 5340 gaagttctac aatgaaccca tcagagatgc
aaagaaaagc acctccgcgg agacggagac 5400 accgcaatcg agcaccgttg
actcacaaga tgaacaaaat ggtgacgtca gaagaacaga 5460 tgaagttgcc
atccaccaag aaggcagagc cgccaacttg ggcacaacta aagaagctga 5520
cgcagttagc tacaaaatat ctagagaaca caaaggtgac acaaacccca gagagtatgc
5580 tgcttgcagc cttgatgatt gtatcaatgg tggtaagtct ccctatgcct
gcaggagcag 5640 ctgcagctaa ctatacctac tgggcctatg tgcctttccc
gcccttaatt cgggcagtca 5700 catggatgga taatcctata gaagtatatg
ttaatgatag tgtatgggta cctggcccca 5760 tagatgatcg ctgccctgcc
aaacctgagg aagaagggat gatgataaat atttccattg 5820 ggtatcatta
tcctcctatt tgcctaggga gagcaccagg atgtttaatg cctgcagtcc 5880
aaaattggtt ggtagaagta cctactgtca gtcccatctg tagattcact tatcacatgg
5940 taagcgggat gtcactcagg ccacgggtaa attatttaca agacttttct
tatcaaagat 6000 cattaaaatt tagacctaaa gggaaacctt gccccaagga
aattcccaaa gaatcaaaaa 6060 atacagaagt tttagtttgg gaagaatgtg
tggccaatag tgcggtgata ttacaaaaca 6120 atgaattcgg aactattata
gattgggcac ctcgaggtca attctaccac aattgctcag 6180 gacaaactca
gtcgtgtcca agtgcacaag tgagtccagc tgttgatagc gacttaacag 6240
aaagtttaga caaacataag cataaaaaat tgcagtcttt ctacccttgg gaatggggag
6300 aaaaaggaat ctctacccca agaccaaaaa tagtaagtcc tgtttctggt
cctgaacatc 6360 cagaattatg gaggcttact gtggcctcac accacattag
aatttggtct ggaaatcaaa 6420 ctttagaaac aagagatcgt aagccatttt
atactgtcga cctaaattcc agtctaacag 6480 ttcctttaca aagttgcgta
aagccccctt atatgctagt tgtaggaaat atagttatta 6540 aaccagactc
ccagactata acctgtgaaa attgtagatt gcttacttgc attgattcaa 6600
cttttaattg gcaacaccgt attctgctgg tgagagcaag agagggcgtg tggatccctg
6660 tgtccatgga ccgaccgtgg gaggcctcgc catccgtcca tattttgact
gaagtattaa 6720 aaggtgtttt aaatagatcc aaaagattca tttttacttt
aattgcagtg attatgggat 6780 taattgcagt cacagctacg ggtgctgtag
caggagttgc attgcactct tctgttcagt 6840 cagtaaactt tgttaatgat
tggcaaaaaa attctacaag attgtggaat tcacaatcta 6900 gtattgatca
aaaattggca aatcaaatta atgatcttag acaaactgtc atttggatgg 6960
gagacagact catgagctta gaacatcgtt tccagttaca atgtgactgg aatacgtcag
7020 atttttgtat tacaccccaa atttataatg agtctgagca tcactgggac
atggttagac 7080 gccatctaca gggaagagaa gataatctca ctttagacat
ttccaaatta aaagaacaaa 7140 ttttcaaagc atcaaaagcc catttaaatt
tggtgccagg aactgaggca attgcaggag 7200 ttgctgatgg cctcgcaaat
cttaaccctg tcacttgggt taagaccatt ggaagtacta 7260 caattataaa
tctcatatta atccttgtgt gcctgttttg tctgttgtta gtctgcaggt 7320
gtacccaaca gctccgaagg gacagcaacc atcgagaacg ggccatgatg acgatggcgg
7380 ttttgtcaaa aagaaaaggg ggaaatgtgg ggaaaagcaa gagagatcag
attgtcactg 7440 tgtctgtgta gaaagaagta gacataggag actcc 7475 2 2129
DNA Human endogenous retrovirus 2 ctacaatgaa cccatcagag atgcaaagaa
aagcacctcc gcggagacgg agacaccgca 60 atcgagcacc gttgactcac
aagatgaaca aaatggtgac gtcagaagaa cagatgaagt 120 tgccatccac
caagaaggca gagccgccaa cttgggcaca actaaagaag ctgacgcagt 180
tagctacaaa atatctagag aacacaaagg tgacacaaac cccagagagt atgctgcttg
240 cagccttgat gattgtatca atggtggtaa gtctccctat gcctgcagga
gcagctgcag 300 ctaactatac ctactgggcc tatgtgcctt tcccgccctt
aattcgggca gtcacatgga 360 tggataatcc tatagaagta tatgttaatg
atagtgtatg ggtacctggc cccatagatg 420 atcgctgccc tgccaaacct
gaggaagaag ggatgatgat aaatatttcc attgggtatc 480 attatcctcc
tatttgccta gggagagcac caggatgttt aatgcctgca gtccaaaatt 540
ggttggtaga agtacctact gtcagtccca tctgtagatt cacttatcac atggtaagcg
600 ggatgtcact caggccacgg gtaaattatt tacaagactt ttcttatcaa
agatcattaa 660 aatttagacc taaagggaaa ccttgcccca aggaaattcc
caaagaatca aaaaatacag 720 aagttttagt ttgggaagaa tgtgtggcca
atagtgcggt gatattacaa aacaatgaat 780 tcggaactat tatagattgg
gcacctcgag gtcaattcta ccacaattgc tcaggacaaa 840 ctcagtcgtg
tccaagtgca caagtgagtc cagctgttga tagcgactta acagaaagtt 900
tagacaaaca taagcataaa aaattgcagt ctttctaccc ttgggaatgg ggagaaaaag
960 gaatctctac cccaagacca aaaatagtaa gtcctgtttc tggtcctgaa
catccagaat 1020 tatggaggct tactgtggcc tcacaccaca ttagaatttg
gtctggaaat caaactttag 1080 aaacaagaga tcgtaagcca ttttatactg
tcgacctaaa ttccagtcta acagttcctt 1140 tacaaagttg cgtaaagccc
ccttatatgc tagttgtagg aaatatagtt attaaaccag 1200 actcccagac
tataacctgt gaaaattgta gattgcttac ttgcattgat tcaactttta 1260
attggcaaca ccgtattctg ctggtgagag caagagaggg cgtgtggatc cctgtgtcca
1320 tggaccgacc gtgggaggcc tcgccatccg tccatatttt gactgaagta
ttaaaaggtg 1380 ttttaaatag atccaaaaga ttcattttta ctttaattgc
agtgattatg ggattaattg 1440 cagtcacagc tacgggtgct gtagcaggag
ttgcattgca ctcttctgtt cagtcagtaa 1500 actttgttaa tgattggcaa
aaaaattcta caagattgtg gaattcacaa tctagtattg 1560 atcaaaaatt
ggcaaatcaa attaatgatc ttagacaaac tgtcatttgg atgggagaca 1620
gactcatgag cttagaacat cgtttccagt tacaatgtga ctggaatacg tcagattttt
1680 gtattacacc ccaaatttat aatgagtctg agcatcactg ggacatggtt
agacgccatc 1740 tacagggaag agaagataat ctcactttag acatttccaa
attaaaagaa caaattttca 1800 aagcatcaaa agcccattta aatttggtgc
caggaactga ggcaattgca ggagttgctg 1860 atggcctcgc aaatcttaac
cctgtcactt gggttaagac cattggaagt actacaatta 1920 taaatctcat
attaatcctt gtgtgcctgt tttgtctgtt gttagtctgc aggtgtaccc 1980
aacagctctg aagggacagc aaccatcgag aacgggccat gatgacgatg gcggttttgt
2040 caaaaagaaa agggggaaat gtggggaaaa gcaagagaga tcagattgtc
actgtgtctg 2100 tgtagaaaga agtagacata ggagactcc 2129 3 2180 DNA
Human endogenous retrovirus 3 gaaaaatttg cctttactat accagccata
aataataaag aaccagccac caggtttcag 60 tggaaagtgt tacctcaggg
aatgcttaat agtccaacta tttgtcagac ttttgtaggt 120 cgagctcttc
aaccagttag agaaaagttt tcagactgtt atattattca ttatattgat 180
gatattttat gtgctgcaga aacgaaagat aaattaattg actgttatac atttctgcaa
240 gcagaggttg ccaatgctgg actggcaata gcatctgata agatccaaac
ctctactcct 300 tttcattatt tagggatgca gatagaaaat agaaaaatta
agccacaaaa aatagaaata 360 agaaaagaca cattaaaaac actaaatgat
tttcaaaaat tactaggaga tattaattgg 420 attcggccaa ctctaggcat
tcctacttat gccatgtcaa atttgttctc tatcttaaga 480 ggagactcag
acttaaatag taaaagaatg ttaaccccag aggcaacaaa agaaattaaa 540
ttagtggaag aaaaaattca gtcagcgcaa ataaatagaa tagatccctt agccccactc
600 caacttttga tttttgccac tgcacattct ccaacaggca tcattattca
aaatactgat 660 cttgtggagt ggtcattcct tcctcacagt acagttaaga
cttttacatt gtacttggat 720 caaatagcta cattaatcgg tcagacaaga
ttacgaataa taaaattatg tgggaatgac 780 ccagacaaaa tagttgtccc
tttaaccaag gaacaagtta gacaagcctt tatcaattct 840 ggtgcatgga
agattggtct tgctaatttt gtgggaatta ttgataatca ttacccaaaa 900
acaaagatct tccagttctt aaaattgact acttggattc tacctaaaat taccagacgt
960 gaacctttag aaaatgctct aacagtattt actgatggtt ccagcaatgg
aaaagcagct 1020 tacacaggac cgaaagaacg agtaatcaaa actccatatc
aatcggctca aagagcagag 1080 ttggttgcag tcattacagt gttacaagat
tttgaccaac ctatcaatat tatatcagat 1140 tctgcatatg tagtacaggc
tacaagggat gttgagacag ctctaattaa atatagcatg 1200 gatgatcagt
taaaccagct attcaattta ttacaacaaa ctgtaagaaa aagaaatttc 1260
ccattttata ttacacatat tcgagcacac actaatttac cagggccttt gactaaagca
1320 aatgaacaag ctgacttact ggtatcatct gcactcataa aagcacaaga
acttcatgct 1380 ttgactcatg taaatgcagc aggattaaaa aacaaatttg
atgtcacatg gaaacaggca 1440 aaagatattg tacaacattg cacccagtgt
caagtcttac acctgcccac tcaagaggca 1500 ggagttaatc ccagaggtct
gtgtcctaat gcattatggc aaatggatgt cacgcatgta 1560 ccttcatttg
gaagattatc atatgttcac gtaacagttg atacttattc acatttcata 1620
tgggcaactt gccaaacagg agaaagtact tcccatgtta aaaaacattt attgtcttgt
1680 tttgctgtaa tgggagttcc agaaaaaatc aaaactgaca atggaccagg
atattgtagt 1740 aaagctttcc aaaaattctt aagtcagtgg aaaatttcac
atacaacagg aattccttat 1800 aattcccaag gacaggccat agttgaaaga
actaatagaa cactcaaaac tcaattagtt 1860 aaacaaaaag aagggggaga
cagtaaggag tgtaccactc ctcagatgca acttaatcta 1920 gcactctata
ctttaaattt tttaaacatt tatagaaatc agactactac ttctgcagaa 1980
caacatctta ctggtaaaaa gaacagccca catgaaggaa aactaatttg gtggaaagat
2040 aataaaaata agacatggga aatagggaag gtgataacgt gggggagagg
ttttgcttgt 2100 gtttcaccag gagaaaatca gcttcctgtt tggataccca
ctagacattt gaagttctac 2160 aatgaaccca tcagagatgc 2180 4 2013 DNA
Human endogenous retrovirus 4 gctagggtga taatggggca aactaaaagt
aaaattaaaa gtaaatatgc ctcttatctc 60 agctttatta aaattctttt
aaaaagaggg ggagttaaag tatctacaaa aaatctaatc 120 aagctatttc
aaataataga acaattttgc ccatggtttc cagaacaagg aactttagat 180
ctaaaagatt ggaaaagaat tggtaaggaa ctaaaacaag caggtaggaa gggtaatatc
240 attccactta cagtatggaa tgattgggcc attattaaag cagctttaga
accatttcaa 300 acagaagaag atagcgtttc agtttctgat gcccctggaa
gctgtataat agattgtaat 360 gaaaacacaa ggaaaaaatc ccagaaagaa
acggaaggtt tacattgcga atatgcagca 420 gagccggtaa tggctcagtc
aacgcaaaat gttgactata atcaattaca ggaggtgata 480 tatcctgaaa
cgttaaaatt agaaggaaaa ggtccagaat tagtggggcc atcagagtct 540
aaaccacgag gcacaagtcc tcttccagca ggtcaggtgc ctgtaacatt acaacctcaa
600 acgcaggtta aagaaaataa gacccaacca ccagtagctt atcaatactg
gccgccggct 660 gaacttcagt atcggccacc cccagaaagt cagtatggat
atccaggaat gcccccagca 720 ccacagggca gggcgccgta ccctcagccg
cccactagga gacttaatcc tacggcacca 780 cctagtagac agggtagtga
actacatgaa attattgata aatcaagaaa ggaaggagat 840 actgaggcat
ggcaattccc agtaatgtta gaaccgatgc cacctggaga aggagcccaa 900
gagggagagc ctcccacagt tgaggccaga tacaagtctt tttcaataaa aatgctaaaa
960 gatatgaaag aaggagtaaa acagtatgga cccaactccc cttatatgag
gacattatta 1020 gattccattg ctcatggaca tagactcatt ccttatgatt
gggagattct ggcaaaatcg 1080 tctctctcac cctctcaatt tttacaattt
aagacttggt ggattgatgg ggtacaagaa 1140 caggtccaaa gaaatagggc
tgccaatcct ccagttaaca tagatgcaga tcaactatta 1200 ggaataggtc
aaaattggag tactattagt caacaagcat taatgcaaaa tgaggccatt 1260
gagcaagtta gagctatctg ccttagagcc tgggaaaaaa tccaagaccc aggaagtacc
1320 tgcccctcat ttaatacagt aagacaaagt tcaaaagagc cctatcctga
ttttgtggca 1380 aggctccaag atgttgctca aaagtcaatt gccgatgaaa
aagcccgtaa ggtcatagtg 1440 gagttgatgg catatgaaaa cgccaatcct
gagtgtcaat cagccattaa gccattaaaa 1500 ggaaaggttc ctgcaggatc
agatgtaatc tcagaatatg taaaagcctg tgatggaatc 1560 ggaggagcta
tgcataaagc tatgcttatg gctcaagcaa taacaggagt tgttttagga 1620
ggacaagtta gaacatttgg aggaaaatgt tacaattgtg gtcaaatcgg tcacttaaaa
1680 aagaattgcc cagtcttaaa caaacagaat ataactattc aagcaactac
aacaggtaga 1740 gagccacctg acttatgtcc aagatgtaaa aaaggaaaac
attgggctag tcaatgtcgt 1800 tctaaatttg ataaaaatgg gcaaccattg
tcgggaaacg agcaaagggg ccagcctcag 1860 gccccacaac aaactggggc
attcccaatt cagccatttg ttcctcaggg ttttcaggga 1920 caacaacccc
cactgtccca agtgtttcag ggaataagcc agttaccaca atacaacaat 1980
tgtcccccac cacaagcggc agtgcagcag tag 2013 5 1224 DNA Human
endogenous retrovirus 5 caagcggcag tgcagcagta gatttatgta ctatacaagc
agtctctctg cttccagggg 60 agcccccaca aaaaatcccc acaggggtat
atggcccact gcctgagagg actgtaggac 120 taatcttggg aagatcaagt
ctaaatctaa aaggagttca aattcatact ggtgtggttg 180 attcagacta
taaaggcgaa attcagttgg ttattagctc ttcaattcct tggagtgcca 240
gtccaggaga caggattgct gaattattac tcctgccata tattaagggt ggaaatagtg
300 aaataaaaag aacaggaggg tttggaagca ctgatccgac aggaaaggct
gcatattggg 360 caagtcaggt ctcagagaac agacctgtgt gtaaggccat
tattcaagga aaacagtttg 420 aagggttggt agacactgga gcagatgtct
ctatcattgc tttaaatcgg tggccaaaaa 480 attggcctaa ccaaaaggct
gttacaggac ttgtcggcat aggcacagcc tcagaagtgt 540 atcaaagtac
ggagatttta cattgcttag ggccagataa tcaagaaagt actgttcagc 600
caatgattac ttcaattcct cttaatctgt ggggtcgaga tttattacaa caatggggtg
660 cggaaatcac catgcccgct ccatcatata gccccacgag tcaaaaaatc
atgaccaaga 720 tgggatatat accaggaaag ggactaggga aaaatgaaga
tggcattaaa attccagttg 780 aggctaaaat aaatcaagaa agagaaggaa
tagggtatcc tttttagggg cggccactgt 840 agagcctcct aaacccatac
cattaacttg gaaaacagaa aaaccggtgt gggtaaatca 900 gtggccgcta
ccaaaacaaa aactggaggc tttacattta
ttagcgaatg aacagttaga 960 aaagggtcat attgagcctt cattctcacc
ttggaattct cctgtgtttg taattcagaa 1020 gaaatcaggc aaatggcgta
tgttaactga cttaagggcc gtaaacgccg taattcaacc 1080 catggggcct
ctccaacctg ggttgccctc tctggccatg atcccaaaag actggccttt 1140
aattataatt gatctaaagg attgcttttt taccatccct ctggcggagc aggattgcga
1200 aaaatttgcc tttactatac cagc 1224 6 23 DNA Artificial Artifical
primer 6 ccactgtaga gcctcctaaa ccc 23 7 26 DNA Artificial
Artificial primer 7 gctggtatag taaaggcaaa tttttc 26 8 250 DNA
Artificial Artificial primer 8 ccactgtaga gcctcctaaa cccataccat
taacttggaa aacagaaaaa ccggtgtggg 60 taaatcagtg gccgctacca
aaacaaaaac tggaggcttt acatttatta gcaaatgaac 120 agttagaaaa
gggtcatatt gagccttcgt tctcaccttg gaattctcct gtgtttgtaa 180
ttcagaagaa atcaggcaaa tggcatatgt taactgactt aaaggccgta aacgccgtaa
240 ttcaacccat 250 9 15 PRT Artificial Artificial peptide 9 Leu Met
Gln Asn Glu Ala Ile Glu Gln Val Arg Ala Ile Cys Leu 1 5 10 15 10 15
PRT Artificial Artificial peptide 10 Ile Pro Tyr Asp Trp Glu Ile
Leu Ala Lys Ser Ser Leu Ser Pro 1 5 10 15 11 15 PRT Artificial
Artificial peptide 11 Ala Asp Gln Leu Leu Gly Ile Gly Gln Asn Trp
Ser Thr Ile Ser 1 5 10 15 12 15 PRT Artificial Artificial peptide
12 Thr Ile Ser Gln Gln Ala Leu Met Gln Asn Glu Ala Ile Glu Gln 1 5
10 15 13 15 PRT Artificial Artificial peptide 13 Glu Lys Ala Arg
Lys Val Ile Val Glu Leu Met Ala Tyr Glu Asn 1 5 10 15 14 15 PRT
Artificial Artificial peptide 14 Met Ala Tyr Glu Asn Ala Asn Pro
Glu Cys Gln Ser Ala Ile Lys 1 5 10 15 15 15 PRT Artificial
Artificial peptide 15 Pro Val Leu Asn Lys Gln Asn Ile Thr Ile Gln
Ala Thr Thr Thr 1 5 10 15 16 15 PRT Artificial Artificial peptide
16 Arg Ser Lys Phe Asp Lys Asn Gly Gln Pro Leu Ser Gly Asn Glu 1 5
10 15 17 15 PRT Artificial Artificial peptide 17 Leu Ser Gly Asn
Glu Gln Arg Gly Gln Pro Gln Ala Pro Gln Gln 1 5 10 15 18 15 PRT
Artificial Artificial peptide 18 Gln Pro Pro Leu Ser Gln Val Phe
Gln Gly Ile Ser Gln Leu Pro 1 5 10 15 19 15 PRT Artificial
Artificial peptide 19 Glu Ile Ile Asp Lys Ser Arg Lys Glu Gly Asp
Thr Glu Ala Trp 1 5 10 15 20 9 PRT Artificial Artificial peptide 20
Val Ser Thr Lys Asn Leu Ile Lys Leu 1 5 21 9 PRT Artificial
Artificial peptide 21 Gly Ile Gly Gln Asn Trp Ser Thr Ile 1 5 22 9
PRT Artificial Artificial peptide 22 Gln Tyr Gly Pro Asn Ser Pro
Tyr Met 1 5 23 9 PRT Artificial Artificial peptide 23 Cys Pro Val
Leu Asn Lys Gln Asn Ile 1 5 24 9 PRT Artificial Artificial peptide
24 Leu Thr Val Trp Asn Asp Trp Ala Ile 1 5 25 9 PRT Artificial
Artificial peptide 25 Lys Phe Asp Lys Asn Gly Gln Pro Leu 1 5 26 9
PRT Artificial Artificial peptide 26 Gly Lys Cys Tyr Asn Cys Gly
Gln Ile 1 5 27 9 PRT Artificial Artificial peptide 27 His Leu Lys
Lys Asn Cys Pro Val Leu 1 5 28 9 PRT Artificial Artificial peptide
28 Gly Arg Lys Gly Asn Ile Ile Pro Leu 1 5 29 9 PRT Artificial
Artificial peptide 29 Phe Ser Ile Lys Met Leu Lys Asp Met 1 5 30 15
PRT Artificial Artificial peptide 30 Pro Ala Val Asp Ser Asp Leu
Thr Glu Ser Leu Asp Lys His Lys 1 5 10 15 31 15 PRT Artificial
Artificial peptide 31 Trp Asn Ser Gln Ser Ser Ile Asp Gln Lys Leu
Ala Asn Gln Ile 1 5 10 15 32 15 PRT Artificial Artificial peptide
32 Val Ser Met Asp Arg Pro Trp Glu Ala Ser Pro Ser Val His Ile 1 5
10 15 33 15 PRT Artificial Artificial peptide 33 Pro Ala Val Gln
Asn Trp Leu Val Glu Val Pro Thr Val Ser Pro 1 5 10 15 34 15 PRT
Artificial Artificial peptide 34 Leu Arg Pro Arg Val Asn Tyr Leu
Gln Asp Phe Ser Tyr Gln Arg 1 5 10 15 35 15 PRT Artificial
Artificial peptide 35 Asn Thr Glu Val Leu Val Trp Glu Glu Cys Val
Ala Asn Ser Ala 1 5 10 15 36 15 PRT Artificial Artificial peptide
36 Ser Ala Val Ile Leu Gln Asn Asn Glu Phe Gly Thr Ile Ile Asp 1 5
10 15 37 15 PRT Artificial Artificial peptide 37 Gln Phe Tyr His
Asn Cys Ser Gly Gln Thr Gln Ser Cys Pro Ser 1 5 10 15 38 15 PRT
Artificial Artificial peptide 38 Asn Arg Ser Lys Arg Phe Ile Phe
Thr Leu Ile Ala Val Ile Met 1 5 10 15 39 9 PRT Artificial
Artificial peptide 39 Pro Tyr Met Leu Val Val Gly Asn Ile 1 5 40 9
PRT Artificial Artificial peptide 40 Ile Phe Lys Ala Ser Lys Ala
His Leu 1 5 41 9 PRT Artificial Artificial peptide 41 Lys Thr Ile
Gly Ser Thr Thr Ile Ile 1 5 42 9 PRT Artificial Artificial peptide
42 Gly Tyr His Tyr Pro Pro Ile Cys Leu 1 5 43 9 PRT Artificial
Artificial peptide 43 Ser Tyr Gln Arg Ser Leu Lys Phe Arg 1 5 44 9
PRT Artificial Artificial peptide 44 Lys Gly Lys Pro Cys Pro Lys
Glu Ile 1 5 45 9 PRT Artificial Artificial peptide 45 Val Glu Val
Pro Thr Val Ser Pro Ile 1 5 46 9 PRT Artificial Artificial peptide
46 Ser Leu Arg Pro Arg Val Asn Tyr Leu 1 5 47 9 PRT Artificial
Artificial peptide 47 Thr Phe Asn Trp Gln His Arg Ile Leu 1 5 48
170 DNA Human endogenous retrovirus 48 cacacaggaa acagctatga
ccatgattac gccaagctca gaattaaccc tcactaaagg 60 gactagtcct
gcaggtttaa acgaattcgc ccttaagggc gaattcgcgg ccgctaaatt 120
caattcgccc tatagtgagt cgtattacaa ttcactggcc gtcgttttac 170 49 170
DNA Human endogenous retrovirus 49 gtgtgtcctt tgtcgatact ggtactaatg
cggttcgagt cttaattggg agtgatttcc 60 ctgatcagga cgtccaaatt
tgcttaagcg ggaattcccg cttaagcgcc ggcgatttaa 120 gttaagcggg
atatcactca gcataatgtt aagtgaccgg cagcaaaatg 170 50 156 DNA
Artificial Artificial primer 50 ttaaacgaat tcgcccttgc tagggtgata
atggggcaaa ctaaaagtaa aattaaaagt 60 aaatatgcct cttatctcaa
gccagttacc acaatacaac aattgtcccc caccacaagc 120 ggcagtgcag
cagtagaagg gcgaatcgcg gccgct 156 51 156 DNA Artificial Artificial
primer 51 ttaaacgaat tcgcccttca agcggcagtg cagcagtaga tttatgtact
atacaagcag 60 tctctctgct tccaggggtt tttaccatcc ctctggcgga
gcaggattgc gaaaaatttg 120 cctttactat acaagcaagg gcgaatcgcg gccgct
156 52 156 DNA Artificial Artificial primer 52 ttaaacgaat
tcgcccttga aaaatttgcc tttactatac cagccataaa taataaagaa 60
ccagccacca ggtttcagct tcctgtttgg atacccacta gacatttgaa gttctacaat
120 gaacccatca gagagcaagg gcgaatcgcg gccgct 156 53 156 DNA
Artificial Artificial primer misc_feature (70)..(70) n is a, c, g,
or t 53 ttaaacgaat tcgcccttct acatgaaccc atcagagatg caaagaaaag
cacctccgcg 60 gagacggagn acaccgcaca agagagatca gattgtcact
gtgtctgtgt agaaagaagt 120 agacatagga gactccaagg gcgaatcgcg gccgct
156 54 24 DNA Artificial Artificial primer 54 cacaggtcaa accgcctagg
aatg 24 55 22 DNA Artificial Artificial primer 55 tcctgctcaa
cttcctgtcg ag 22 56 26 DNA Artificial Artificial primer 56
tctttagcga gacgctacca tggcta 26 57 27 DNA Artificial Artificial
primer modified_base (25)..(25) n = t and/or c misc_feature
(25)..(25) n is a, c, g, or t 57 cattccttgt ggtaaaactt tccantg 27
58 25 DNA Artificial Artificial primer modified_base (23)..(23) n =
t and/or c misc_feature (23)..(23) n is a, c, g, or t 58 ccccttggaa
tactcctgtt ttntg 25 59 81 PRT Artificial Artificial peptide 59 Ile
Lys Lys Lys Ser Gly Lys Trp Arg Met Leu Thr Asp Leu Arg Ala 1 5 10
15 Ile Asn Ser Val Ile Gln Pro Met Gly Ala Leu Gln Pro Gly Leu Pro
20 25 30 Ser Pro Ala Ile Ile Pro Lys Asn Trp Pro Leu Val Val Ile
Asp Leu 35 40 45 Lys Asp Ser Phe Phe Thr Ile Pro Leu Ala Asp Gln
Asp Cys Glu Trp 50 55 60 Phe Ala Phe Ile Ile Pro Ala Val Asn Asn
Leu Gln Pro Ala Lys His 65 70 75 80 Phe
* * * * *